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The re-emergence of Zika virus (ZIKV), an arbovirus, poses a major global
human health concern because of its ability to cause congenital abnormalities and
neurological diseases. While many candidate vaccines and antiviral drugs are in the
developmental pipeline, none have been approved for use against ZIKV infection. This
dissertation describes the characterization of one vaccine and two antiviral drug
candidates against ZIKV infection. A bacterial ferritin-based nanoparticle vaccine,
termed zDIII-F, is designed to display multiple copies of ZIKV E protein domain III on
its surface. These stable nanoparticles are shown to induce robust antibody-mediated
protection against lethal ZIKV infection in mice. Additionally, passive transfer of sera
from zDIII-F immunized mice also conferred protection in animals following ZIKV
challenge. By employing a homology-based modelling approach, we predicted the
structure of ZIKV RNA-dependent RNA polymerase (RdRp) and used it to screen for
small molecule compounds that bind the viral RdRp. Among the top 10 compounds with
high docking scores, we observed that the molecule with the highest score, TPB,
strongly suppressed ZIKV replication in vitro and in vivo. With the ability to target the
conserved regions of flavivirus RdRp, a high selective index of 206 combined with a low
molecular weight of ~500 daltons, TPB promises to be an excellent candidate for

development as an anti-ZIKV as well as an anti-flavivirus drug. Analysis of ZIKV
genome sequences suggested the presence of conserved guanine (G)-rich motifs that can
fold under physiological conditions to form secondary structures called G-quadruplexes.
Such structures, when stabilized, can inhibit transcription, translation, and replication.
We have demonstrated that stabilization of ZIKV genome G-quadruplexes by Gquadruplex-binding ligands, BRACO-19 and TMPyP4, significantly suppressed ZIKV
protein synthesis and replication. Therefore, we propose further development and
potential use of G-quadruplex-binding ligands as a strategy for treatment of ZIKV
infection. Overall, the studies described in this dissertation significantly contribute to
development of anti-ZIKV therapeutics.
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CHAPTER I: INTRODUCTION

1.1. Classification of Zika virus
Zika virus (ZIKV) is a member of the family Flaviviridae. Viruses of this family
are enveloped and carry a positive sense, non-segmented single stranded RNA genome of
about 9-13 kilo bases (kb) in length. The family Flaviviridae is classified into four
genera: Flavivirus, Pestivirus, Hepacivirus and Pegivirus (Simmonds et al., 2017). The
genus Flavivirus encompasses more than 70 arthropod-borne viruses. These are further
categorized based on vector transmission: (i) Tick vectored viruses include Alkhurma
hemorrhagic fever virus (AHFV), Kyasanur Forest Disease (KFD), Omsk hemorrhagic
fever virus (OHFV) and Tick-borne Encephalitis (TBE), and (ii) Mosquito vectored
viruses include, dengue virus (DENV), Japanese Encephalitis Virus (JEV), yellow fever
virus (YFV), West Nile virus (WNV), and ZIKV (Kuno et al., 1998). Most of them are
responsible for fatal hemorrhagic fever or neurological disease such as encephalitis in
humans.
Serologic and genome analyses of ZIKV suggest the existence of only one single
serotype with three distinct genetic lineages: East African (that includes the first isolate
from Uganda, MR766 in 1947), West African, and Asian, including the first isolate from
Malaysia,Asia (P6-740) in 1966 and all contemporary strains from Asia, Oceania, and the
Americas (Dowd et al., 2016; Lanciotti et al., 2008; Lanciotti et al., 2016; Musso et al.,
2016a).

1.2. ZIKV and diseases associated with ZIKV infections
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The primary mode of ZIKV transmission is through mosquito bite; however, the
virus has also been shown to be transmitted sexually (Atkinson et al., 2016; Foy et al.,
2011; Turmel et al., 2016), from mother to fetus (Fiorentino and Montero, 2016; Pomar et
al., 2018; Zanluca et al., 2018), through blood transfusion (Liu et al., 2019; Musso et al.,
2016b) and also by contact with contaminated body fluids such as saliva and urine (Brasil
et al., 2016; D'Ortenzio et al., 2016; Mlakar et al., 2016; Russell et al., 2017). The
incubation period of disease is estimated to range from 3 to 14 days. The majority
(≥80%) of individuals infected with ZIKV do not show any symptoms while some
develop mild self-resolving symptoms including fever, rash, conjunctivitis, headache,
malaise, muscle, and joint pain lasting for 2 to 7 days. However, in a very small number
of cases, infections can lead to severe diseases, such as Guillain-Barré syndrome (GBS),
an autoimmune disease of the peripheral nervous system in adults and congenital Zika
syndrome (CZS) in developing fetuses that includes a variety of pathological
abnormalities such as craniofacial, musculoskeletal, ocular, and pulmonary
malformations (de Paula Freitas et al., 2016; de Paula Guimaraes et al., 2019; Miranda et
al., 2016; Russell et al., 1984; Zacharias et al., 2017). In addition, infant case in the recent
Brazil outbreak were associated with a severe reduction in the size of the skull and
developmental deficits in the brain, a condition known as microcephaly (Alvarado and
Schwartz, 2017; Panchaud et al., 2016). Furthermore, studies have suggested that ZIKV
infection may be responsible for reduced fertility in men (Avelino-Silva et al., 2018).
ZIKV infection also causes conjunctivitis persistent chorioretinal lesions, and uveitis in
humans (Manangeeswaran et al., 2018; Miner et al., 2016). Unlike previous ZIKV
outbreaks, genomic changes responsible forthe high pathogenicity of the virus in recent
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outbreaks are unknown.

1.3. History and emergence of ZIKV
ZIKV was first isolated in 1947 from the blood sample of a sentinel rhesus
monkey in the Zika forest of Uganda (Dick et al., 1952). Although the first case of human
infection by ZIKV was described in Nigeria in the early 1950s, only sporadic outbreaks
were reported in Africa and Asia over the next few decades. The virus re-emerged in
2007 causing an outbreak in the Yap Island of Federated States of Micronesia, with the
majority of symptomatic patients exhibiting fever, rash, and arthritis/arthralgia (Duffy et
al., 2009). A larger ZIKV outbreak occurred in French Polynesia and other Pacific
Islands in late 2013, where, in addition to the above-described symptoms, conjunctivitis
was also noted (Cao-Lormeau et al., 2014; Musso et al., 2014). The virus was
subsequently detected for the first time in Brazil in 2015, causing infections of epidemic
proportions (Zanluca et al., 2015), although epidemiological studies through viral
genome sequence analysis suggest that the virus may have been circulating in the
northeastern part of the country as early as late 2013 (Grubaugh et al., 2018). The virus
rapidly spread to many countries in the Americas and other parts of the world (Faria et
al., 2017; Weaver et al., 2016). The incidences of ZIKV infections in the Americas
peaked in early 2016 with the cumulative number of documented and suspected cases
exceeding 1 million. However, the the incidence of ZIKV infectionin the Americas and
the rest of the world has waned significantly after 2017.
The ZIKV epidemic in Brazil, as well as other countries, was linked to
devastating CZS including microcephaly, congenital malformation, and fetal demise,
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particularly when women are infected with the virus during the first trimester of
pregnancy (Brasil et al., 2016; Coyne and Lazear, 2016; Heymann et al., 2016; Hoen et
al., 2018; Mlakar et al., 2016; Panchaud et al., 2016). ZIKV infections were also found to
be associated with GBS in adults, an auto-immune disease of the peripheral nerves that
can result in muscle weakness and paralysis (Barbi et al., 2018; Besnard et al., 2014;
Mendez et al., 2017; Styczynski et al., 2017). While ZIKV infections prior to 2013 were
mostly associated with mild disease symptoms, the new severe disease forms associated
with the virus infections such as GBS and CZS led the World Health Organization
(WHO) to declare ZIKV a Public Health Emergency of International Concern (2016).
This prompted the global health and research community to not only study the biology
and pathogenesis of the virus but also devise strategies for prevention and control
measures, including the development of safe and efficacious vaccines and antivirals
against ZIKV.

1.4. ZIKV virion structure
In the recent years, two independent groups have solved the cryo-EM structure of
the mature ZIKV virion particle at atomic resolution of 3.8 Å. Similar to other closely
related flaviviruses, the ZIKV particle is spherical (Shi and Gao, 2017), with a size of
50nm for the mature particle and 60nm for the immature particle.. (Barreto-Vieira et al.,
2016; Heinz and Stiasny, 2017; Prasad et al., 2017). The mature ZIKV particle consists of
a of ~11 kb long, non-segmented, positive-sense RNA genome, which is enclosed by the
capsid protein (Boyer et al., 2018) and further surrounded by a host derived lipid bilayer
into which 180 copies of each of the membrane (M) and envelope (E) glycoproteins are
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anchored through their respective transmembrane regions (Dai et al., 2016; Kuhn et al.,
2002). The E protein forms the outermost layer of the virus particle (Fig 1.1), which
protects the viral genome from the external environment and is known to interact with
host cell surface during infection (Shi and Gao, 2017). The monomeric form of ZIKV E
protein is embodied with four subdomains: three ectodomains (domains I, II and III) and
a stem –transmembrane domain. Structural analysis of a mature virion shows that the two
E protein monomers dimerize and three such dimers lie parallel to each other adopting a
raft configuration. A mature virion exhibits icosahedral structure and contains a total of
30 such rafts. One half of a raft constitutes an asymmetric unit of the virion resulting in
the presence of 90 such asymmetric units in a mature ZIKV particle. The virion consists
of 180 units of the E and M proteins forming the raft configuration (Fig. 1.1). The M
protein, unlike the E protein, is short and resides under the E protein, displaying a similar
icosahedral organization (Dai et al., 2016; Shi and Gao, 2017; Sirohi et al., 2016).

1.5. Genome organization of ZIKV
Similar to flaviviruses, ZIKV also contains a single-stranded positive-sense RNA
genome ~11 kb in length. The viral genome (Fig. 1.2 A) has a single open reading frame
(ORF) of ~10,200 bases and is flanked by 5′ untranslated region (UTR) and 3′ UTR (van
Hemert and Berkhout, 2016). The 5’ UTR and 3’ UTRs are about 106 and 430
nucleotides long, respectively. In addition, the genome has a type I cap structure and 3’
UTR contains multiple pseudoknot structures and lacks poly (A) tails. The ORF encodes
a single polyprotein of ~3,400 amino acids (aa) in length, which is translated in the
cytoplasm and in association with the rough endoplasmic reticulum of the infected cells
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Fig. 1.1. Structure of ZIKV particles. (A) Left and right images represent surfaceshaded, radially colored immature and mature ZIKV particles. The immature particle
contains 60 trimers of prM-E heterodimers, while the mature particles contain 90 dimers
of conformationally rearranged heterodimers of M-E along with loss of pr peptide by
furin cleavege. The images were adapted from Sirohi, D. and Kuhn, R.J. (2017). (B)
Schematic representation of a prototypical flavivirus (including ZIKV) immature and
mature particle showing a cross-sectional organization of viral proteins and RNA. sE,
soluble E protein. The image is from Heinz, F.X. and Stiansy, K. (2017).
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Fig. 1.2. ZIKV genome organization, encoded proteins, and their topology. (A) The
viral genome is shown as a black line with a cap structure at the 5’ end, followed by an
untranslated region (5’UTR), various proteins (with amino acid residue length) generated
from a single open reading frame that is translated from the genome, and the 3’ UTR. (B)
Topology of the viral proteins is shown. Colored arrows show various protease cleavage
sites for generation of the mature proteins. A small protein (2K) present between NS4A
and NS4B is entirely membrane-associated. The cylindrical structures represent
membrane-associated domains of the proteins. Image redrawn from Tan et.al, 2020.
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(Hamel et al., 2015). The single polyprotein is cleaved and processed by viral and host
proteases (Fig. 1.2 B) to generate three structural (capsid, C; precursor-membrane, prM;
and envelope, E) proteins present at the amino-terminus and seven non-structural (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins present at the carboxy-terminus
(Medeiros et al., 2007). The proteins of ZIKV have structurally and functionally
equivalent counterparts in other members of Flaviviridae such as DENV, WNV, YFV
and JEV. The structural proteins are involved in virion formation, protection of the viral
genome, attachment to , and entry into the host cells (Lindenbach and Rice, 2013). The
NS proteins are associated with the endoplasmic reticulum (ER) and participate in
genome replication, polyprotein processing, virion assembly, and evasion of host
antiviral responses (Grant et al., 2016; Kumar et al., 2016; Pierson and Diamond, 2015)

1.6. Protein products
1.6.1. Capsid (C) protein
The three proteins that are part of the mature Zika virion are: the capsid protein
(C), the membrane protein (M), and the envelope protein (E). Following infection, the
viral genome is first translated in the cytoplasm as a single large polypeptide containing
the viral C protein at its amino-terminus. The C proteins plays a central role in the ZIKV
assembly process (Samsa et al., 2009; Shang et al., 2018). It is a small cytosolic protein
of 122 amino acids (aa) long with a molecular weight of approximately 14 kDa. The
mature C protein that is incorporated into virions is smaller. The C protein contains a
highly positively charged loop followed by five alpha helices (α1- α5) at the N-terminal
end (Tan et al., 2020). The α5 helix is present just upstream of the prM protein. In order
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to make a mature C protein, a sequential cleavage occurs which is executed by both
cellular and viral proteases. The first cleavage, mediated by a cellular protease, occurs at
the signal peptide present in the α5-prM junction, and separates C from prM. The second
cleavage, mediated by the viral proteases NS2B/Ns3, occurs at the capsid helix α4–α5
junction, and results in release of the 98 aa mature capsid protein (Tan et al., 2020). The
mature C protein forms a homodimer. During virus assembly, the mature C protein binds
to the viral RNA and to the trans-membrane domains of E and M proteins (Freire et al.,
2015; Ni and Cheng Kao, 2013).

1.6.2. Precursor membrane (prM) and membrane (M) proteins
The prM protein consists of ~166 amino acids and is cleaved into pr and M
proteins as the assembled virions mature during virus egress. The M protein consists of
~75 amino acids and is essential to virus assembly (Khou and Pardigon, 2017; Kuno et
al., 1998). Its chaperone-like activity promotes proper folding and maturation of E
protein (Konishi and Mason, 1993; Lorenz et al., 2002; Yoshii et al., 2012). During virus
assembly, the prM protein protects the E protein from premature fusion due to the low pH
environment in the transport vesicle while the immature virion traverses the ER and
trans-Golgi network (Guirakhoo et al., 1991; Heinz et al., 1994; Nambala and Su, 2018).
Host cellular furin protease cleaves the pr portion from the M resulting in formation of
mature virus particle. The mature virions subsequently become fusogenic and infectious
(Nambala and Su, 2018; Zhang et al., 2018). It has been reported that the S139Nin prM is
involved in neurovirulence in neonatal mice and may explain the association of ZIKV
with congenital birth defects (Krauer et al., 2017; Yuan et al., 2017).
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1.6.3. Envelope (E) protein
The envelope protein is 504 aa long with a molecular weight of ~53kDa (Dai et
al., 2016). The E protein is key to virus infection and is known to interact with multiple
cell surface receptors like DC-SIGN, AXL, Tyro3 and TIM-1. This interaction facilitates
virus entry into host cells. The viral E protein is an important target for neutralizing
antibodies (Agrelli et al., 2019; Gallichotte et al., 2019; Hamel et al., 2015; Richard et al.,
2017) and the entire protein or various domains of the protein have been used to develop
subunit vaccine candidates.
The E monomer protein has one transmembrane (TM) domain and three
structurally distinct ectodomains, I, II, and III. The domain I (DI) is located in the middle
to link DII which contains the hydrophobic fusion loop with DIII fold at its C-terminus.
A total of ninety E protein dimers are arranged in an icosahedral symmetry and exhibit a
“herringbone”- like pattern (Modis et al., 2004). The virion surface is covered with 30
rafts and each raft structure is formed by three parallel array of E dimers. The
hydrophobic fusion loop located within DII is covered by the DIII of the neighboring
protomer in pre-fusion state. After synthesis, E protein heterodimerizes with prM rapidly
resulting in proper folding (Li et al., 2008). The heterodimers in the ER membrane form
trimeric spikes and bud off with nucleocapsid containing immature virions. Subsequently,
the fusion loop is exposed and inserts into the cell membrane leading to endosome
acidification and formation of mature virus particles (Li et al., 2008; Sirohi et al., 2016;
Zhang et al., 2017). Like other Flavivirus members, ZIKV E protein is the major target
for the neutralizing antibody responses (Beltramello et al., 2010; Oliphant et al., 2005)
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and contains multiple neutralizing epitopes. ZIKV E specific antibodies have been used
for the detection of ZIKV infection. (Sapparapu et al., 2016; Zhao et al., 2016). The
structural changes in the E protein can affect the virus ligand interactions like cell
receptors, antibodies, and drugs (Zhang et al., 2017). Therefore, E protein targeted drugs
and monoclonal antibodies have been used to block the entry of ZIKV (Li et al., 2019).

1.6.4. Nonstructural (NS) proteins
1.6.4.1. NS1
ZIKV NS1 is a 352 aa multifunctional, highly immunogenic glycoprotein.
Depending on its glycosylation status, the molecular weight of the protein ranges from
~46 to ~54 kDa (Muller et al., 2012; Rastogi et al., 2016). Flavivirus NS1 is known to
homodimerize and translocate to the ER lumen where it aides in virus replication. The
NS1 monomer contains three domains: (i) a β- hairpin domain present at the amino (N)terminal, (ii) a wing domain, and (iii) β- ladder domain at the carboxy (C)-terminal
(Hilgenfeld, 2016). Structural studies suggest interaction between the flexible loop
present at the N- terminal of NS1 with E and prM and these interactions are essential for
the production of mature virus particles (Scaturro et al., 2015). The subcellular
localization of NS1 can either be in the cytosol or associated with the cell membrane or
can also be secreted as hexamers (Somnuke et al., 2011; Viranaicken et al., 2017). In
addition to its role in virus replication, the NS1 protein is also known to play an
important role in the evasion of host immune response (Rastogi et al., 2016). The
presence of NS1 can also be useful in the diagnosis of ZIKV infection (Kam et al., 2019).
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1.6.4.2. NS2
Flavivirus NS2 is encoded as a single immature polypeptide which is further
processed into the mature proteins, NS2A and NS2B. The aa length of NS2A and NS2B
are 226 and 130, respectively (Sirohi and Kuhn, 2017). The flavivirus NS2 protein is a
transmembrane polypeptide that associates with the ER membranes and orchestrates the
formation of viral replication complexes (Xie et al., 2013). NS2A functions as an
antagonistic factor to the host immune responses and is required for the proteolytic
processing and proper functioning of NS1 (Leung et al., 2008). NS2B is known to
associate with NS3 and serves as an essential cofactor for NS2B-NS3 protease activity
(Arias et al., 1993; Xie et al., 2013). It has been demonstrated that an alanine to valine
substitution at residue 175 of NS2A (A175V) affects viral RNA synthesis and leads to
viral attenuation in immunodeficient mice (Marquez-Jurado et al., 2018).
1.6.4.3. NS3
NS3 is 617 aa long with a molecular weight of ~82 kDa and is the second largest
protein encoded by the ZIKV genome after NS5 protein (Rodriguez et al., 2019). The
NS3 protein contains two separate domains, namely, (i) a serine and a chymotrypsin
protease domain (NS3Pro) at the N-terminal region, and (ii) RNA helicase (NS3Hel) and
RNA triphosphatase (NTPase) domain at the C-terminal region (Hill et al., 2018; Li et al.,
2018b; Phoo et al., 2018). The C-terminal helicase domain comprises NTPase pocket and
a RNA binding tunnel (Tian et al., 2016a; Tian et al., 2016b). The NTPase pocket
contains a highly flexible P-loop while the RNA binding tunnel contains a RNA binding
loop that are important for the helicase function of NS3 (Giri et al., 2016; Tian et al.,
2016a; Tian et al., 2016b). Additionally, NS3 associates with NS2B and forms an active
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protease complex (Falgout et al., 1991). NS3 is known to interact with NS5 protein to
stimulate its helicase activity (Xu et al., 2019). ZIKV NS3 has also been implicated in
abnormnal brain development and has been shown to induce brain calcification in human
fetuses, contributing to the ZIKV induced pathology in the fetal brain (Chen et al., 2021).
These findings demonstrate the critical involvement of NS3 protein in flavivirus
replication, virion assembly, and pathogenesis (Chambers et al., 1993) and therefore, can
serve as an important target to curb flavivirus replication. Indeed, several inhibitors
targeting the ZIKV NS3 have been developed in recent years and they have been shown
to inhibit virus replication (Choudhry et al., 2019; Coluccia et al., 2020; Kumar et al.,
2018; Pathak et al., 2020).

1.6.4.4. NS4
ZIKV NS4 consists of two mature proteins, NS4A and NS4B which are cleaved
from the immature NS4 peptide by NS3 and other cellular proteases (Sun chen, 2017).
NS4A is 127 aa and NS4B is 251 aa in length and are separated by a small linker, 2K,
peptide of 23 amino acids (Sirohi and Kuhn, 2017). NS4 serves as a critical component of
the viral replication complex, responsible for the replication of the viral genomic RNA. It
also plays a crucial role in evasion of host immune mechanisms by antagonizing the
JAK-STAT and RLR signaling pathways (Gerold et al., 2017; Ma et al., 2018).
Additionally, ZIKV NS4A and NS4B have been implicated in ZIKV induced disease and
are shown to induce autophagy and subsequent cell death in human neural stem cells by
inhibiting the Akt-mTOR signaling cascade. This is a probable mechanism by which
ZIKV depletes neural stem cells in a developing brain and likely causes microcephaly
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(Liang et al., 2016).

1.6.4.5. NS5
NS5 is 903 aa in length and thus the largest protein encoded by ZIKV. It is the
viral RNA-dependent RNA polymerase (RdRp) that is responsible for replication of the
viral genome. NS5 is the most conserved flavivirus protein (Chen et al., 2018). NS5
consists of two domains; (i) the amino-terminal methyltransferase (MTase) domain and
(ii) the carboxy-terminal RNA-dependent RNA polymerase (RdRp) domain (Davidson,
2009). Both domains work together to catalyze RNA polymerization (Elshahawi et al.,
2019). During virus genome replication, the RdRp domain uses the genomic positivesense RNA as a template to synthesize the negative-sense RNA which in turn serves as
the template for generating more positive-sense strands for progeny production (Bollati et
al., 2010). The MTase domain interacts with NS3 to facilitate the capping of the newly
synthesized viral RNA at guanine N-7 and ribose 2’-O positions (Zhou et al., 2007).
Additionally, NS5 plays a major role in antagonizing the host immune response and
inducing the immune evasion mechanisms. It has been demonstrated that ectopic
expression of ZIKV NS5 results in the proteasomal degradation of human signal
transducer and activator of transcription 2 (STAT2), a crucial component of type 1
interferon induced antiviral immunity, thereby leading to suppression of host antiviral
response (Grant et al., 2016; Kumar et al., 2016; Wang et al., 2017). Additionally, recent
studies also demonstrate an additional mechanism by which the NS5 protein of ZIKV
may inhibit host antiviral response. The interaction between TBK1 and NS5 results in the
deactivation of TBK1, thus preventing TBK1 mediated IRF3 phosphorylation and type 1
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IFNs production (Best, 2017; Lin et al., 2019). These studies demonstrate the pivotal role
of NS5 in viral replication and host immune evasion and form the basis of antiviral drug
design targeting the viral NS5 protein (Pattnaik et al., 2018; Sariyer et al., 2019; Yuan et
al., 2020).

1.7. Life cycle of ZIKV
The dramatic increase of ZIKV infection and its association with neuronal
diseases in 2015-16 can be attributed to rapid urbanization with increased population
growth, lack of sanitation, and ineffective mosquito control. The virus maintains a
sylvatic cycle in non-human primates and mosquitoes in the forest (Valentine et al.,
2019). In the urban cycle, the virus is transmitted to humans by Aedes group of
mosquitoes and then to other humans by either mosquito vectors or through body fluids
from infected individuals. Typically, virus inoculation in humans occurs by mosquito
bites in the epidermal cells and is transported to the nearest draining lymph node by
specialized skin-resident dendritic cells, known as Langerhans cells (Hamel et al., 2015).
This leads to the infection of other cell types that include mononuclear phagocytic cells
like monocytes and macrophages which results in viremia. ZIKV has a broad tissue
tropism and is known to infect cells in many different organs such as the brain, eyes,
spleen, and organs of the reproductive system. The virus is known to infect the placentas
of developing fetuses and can also infect the fetus in utero resulting in a variety of
developmental complications and fetal demise (Miner and Diamond, 2017).
The life cycle of ZIKV (Fig. 1.3) is a multistep process, which begins with the virion E
protein attaching to the cell surface receptors such as DC-SIGN, AXL, Tyro3 and TIM-1
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(Hamel et al., 2015; Richard et al., 2017; Sirohi and Kuhn, 2017). This facilitates virus
entry into host cells through clathrin-mediated endocytosis (Li et al., 2020). Furthermore,
the endocytosed virion travels to early endosome compartment where the acidic pH of the
early endosome triggers conformational modifications in the virion leading to the release
of the genomic viral RNA into the cytoplasm subsequently leading to initiation RNA
translation (Gratton et al., 2019; Mohd Ropidi et al., 2020). The viral RNA is translated
into a single polypeptide containing an ER localization signal which leads to
translocation of the polyprotein onto the ER surface where it is cleaved by host and viral
proteases to form the structural and non-structural proteins (Tomar et al., 2017). Viral
genome replication is initiated by the newly synthesized NS proteins to generate a full
complement of the negative-sense RNA that can form a dsRNA intermediate with the
incoming viral genome. The negative-sense RNA then serves as the template for new
viral genome copies (Lindenbach and Rice, 2003). The newly synthesized copies of the
viral genome are further translated and replicated leading to accumulation of viral
proteins and genome copies in the infected cell. The viral proteins interact with different
ER resident chaperones to undergo post-translational modifications resulting in the
assembly of immature progeny virions. During transport through the secretory pathway,
prM molecules are cleaved by the host furin-like proteases in the trans-Golgi region into
pr and M polypeptides, which results in mature virus particles that exit the host cell by
budding (Caldas et al., 2020; Cortese et al., 2017; Hamel et al., 2015; Mohd Ropidi et al.,
2020).

1.8. Animal models
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Fig. 1.3. Schematic of ZIKV life cycle. Virus binds to cell surface receptor(s) through
the viral E protein (1) and is internalized by receptor-mediated endocytosis (2). Low pHmediated conformational change in the E protein leads to the fusion of the endosomal
membrane with the viral envelope (3). The genomic RNA is released (4) for translation
(5) to produce viral proteins by the ER-associated ribosomes (5). The viral genome is
replicated by the viral replication proteins to produce more copies of the genomic RNA
(6), which are then assembled in the ER along with the structural proteins (7) to produce
immature particles. Transport through the trans-Golgi network allows virus maturation
(8) to occur and the virus is finally released from the cell (9) by exocytosis.
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The recent ZIKV outbreak in 2015-16 was a public health emergency due to
increase in the rate of ZIKV induced microcephaly in infants and GBS in adults. In
response to this thread, different animal models to investigate ZIKV biology and
pathogenesis and to evaluate vaccines and therapeutics were developed. In the past few
years, various strains of ZIKV inoculated at different infectious dosages were studied in
multiple mouse strain like C57BL/6, BALB/c and CD-1 mice models (Bradley and
Nagamine, 2017; Morrison and Diamond, 2017). The inoculation studies in wild-type
mice exhibited no disease signs or transient viremia with low levels or no detection of
viral RNA/infectious virus titer in different tissue reservoirs such as the brain, spleen,
liver, blood, and the reproductive system. (Larocca et al., 2016; Lazear et al., 2016; Rossi
et al., 2016b). A possible mechanism for ZIKV infection resistance in immunocompetent
mice is that, unlike in humans, ZIKV NS5 does not efficiently degrade murine STAT2,
resulting in the inhibition of ZIKV replication (Grant et al., 2016; Kumar et al., 2016).
Studies have suggested that immunocompromised mice, especially mice deficient
in the IFN signaling pathway, are highly susceptible to ZIKV infection, thus serving as
models for studies on ZIKV pathogenesis (Bradley and Nagamine, 2017; Morrison and
Diamond, 2017). ZIKV infections in immunocompromised mice models such as
interferon  β receptor knock out (A129) mice , interferon  β and  receptor knock out
(AG129), and Irf3, Irf5, Irf7 as well as STAT1 gene knockout animals present with
symptoms including ruffled fur, ataxia, tremor, weakness, and limb paralysis, and
succumb to infection in an age dependent manner. Such models can be used to
recapitulate ZIKV infections in humans (Aliota et al., 2016a; Kamiyama et al., 2017;
Lazear et al., 2016; Li et al., 2016a; Rossi et al., 2016b; Weger-Lucarelli et al., 2017).
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Due to the high cost and tardy availability of such knockout mouse strains, alternative
approaches such as pre-treatment with IFNAR1 blocking antibodies in wild type
C57BL/6 mice and other models such as guinea pigs and hamsters are being developed to
counter such issues (Siddharthan et al., 2017; Smith et al., 2017). Several groups have
also used non-human primates (NHPs) such as pigtail macaques, rhesus and cynomolgus
macaques to study ZIKV biology and pathogenesis owing to increased clinical relevance
(Adams Waldorf et al., 2011; Aliota et al., 2016b; Dudley et al., 2016; Osuna et al.,
2016).

1.9. Current status of ZIKV vaccines
The unprecedented magnitude of the ZIKV epidemic and the severity of disease
prompted the global research community to understand the immunopathogenic
mechanisms of the virus and to rapidly develop safe and efficacious vaccines. Multiple
ZIKV vaccine candidates under various platforms have been developed over the last four
years (Barouch et al., 2017; Diamond et al., 2019; Poland et al., 2019; Shan et al., 2018).
Since ZIKV shares considerable genetic and structural similarities with other flaviviruses,
cross-reactive and/or poorly neutralizing antibodies could be generated as a result of
flavivirus/ZIKV infection or vaccination. Such antibodies can potentially lead to
antibody-dependent enhancement (ADE) of virus infection and disease (Bardina et al.,
2017; Castanha et al., 2017; Dejnirattisai et al., 2010; Dejnirattisai et al., 2016; Halstead,
2003; Kawiecki and Christofferson, 2016; Priyamvada et al., 2016). Thus while
considering developing vaccine candidates for ZIKV, attention must be placed on
preventing ADE. In this regard, recent studies have demonstrated that the DIII domain of

20

the ZIKV E protein induces a neutralizing antibody response without exhibiting ADE
(Cabral-Miranda et al., 2019; Tai et al., 2019).
Several different ZIKV vaccine candidates under different platforms have now
been developed and tested in preclinical and clinical trials (Pattnaik et al., 2020). These
include nucleic acid vaccines (DNA and RNA vaccines), inactivated whole virus
vaccines, live attenuated vaccines, virus-vectored vaccines, purified protein antigen
vaccines, and virus-like particles (Fig. 1.4).

1.9.1. Nucleic acid vaccines
Both DNA- and mRNA-based vaccines have been developed and tested in
preclinical studies. The proof-of-concept for use of a DNA vaccine against ZIKV was first
developed using plasmids containing coding sequences of the viral prM-E regions, and
later using the coding sequence of viral NS1, and examining immune responses in mice
(Larocca et al., 2016) and NHPs (Abbink et al., 2016). In these studies, the plasmid
constructs generated prM-E, M-E (with deletion of pr region) or NS1 proteins and induced
high levels of neutralizing antibodies when the plasmid DNA was injected into mice or
NHPs (Abbink et al., 2016; Dowd et al., 2016; Larocca et al., 2016). The NS1-specific
antibodies were found to be long-lasting and were responsible for Fc-mediated effector
functions for protection (Bailey et al., 2018). Additionally, other DNA vaccines made by
replacing the signal sequence of ZIKV prM-E at the N-terminus and 98 C-terminal aa of E
with corresponding sequences of JEV prM-E or the signal sequence of immunoglobulin
(Muthumani et al., 2016) were also shown to protect immunocompromised mice during
pregnancy from disease, against vertical transmission and fetal demise (Jagger et al., 2019).
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Due to the inherent instability of mRNA and its ability to activate innate immune
signaling pathways, use of modified nucleosides during in vitro transcription was shown
to render mRNAs less immunogenic (Kariko et al., 2005) and also enhanced its
translational capacity (Andries et al., 2015; Kariko et al., 2008). Thus, prM-E mRNAs
synthesized in vitro in the presence of the modified nucleoside, 1-methylpseudouridine
and encapsulated with lipid nanoparticles (LNP) induced a robust neutralizing antibody
response and ZIKV-specific cellular responses that conferred complete protection from
virus challenge when injected into immunocompetent mice and rhesus macaques (Pardi
et al., 2017; Richner et al., 2017a). Using a prime-boost approach, these mRNA vaccines
were shown to mediate protection against ZIKV virus-induced congenital disease
(Richner et al., 2017b) and protect immunocompetent and immunocompromised mice
during pregnancy (Jagger et al., 2019). With the development of infectious molecular
clones of many wild-type and vaccine strains of flaviviruses, it has been possible to
generate live attenuated vaccine candidates through genetic manipulation by two major
strategies: (i) introducing specific attenuating mutations into ZIKV genome, and (ii)
generating chimeric flaviviruses expressing the prM-E genes of ZIKV in the genetic
background of DENV, JEV, or YFV. Engineering 10 or 20 nt deletions within the 3′UTR of ZIKV genome resulted in virus attenuation. The virus conferred sterilizing
immunity in immunocompromised mice and in NHPs. Responses in mice exhibited high
titers of neutralizing antibodies and a robust T cell response, and prevented testis damage
by wild type ZIKV (Shan et al., 2017a; Shan et al., 2017b). Additionally, studies from
our laboratory have shown that by eliminating glycosylation sites in E and/or NS1
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Fig. 1.4. Schematic of various ZIKV vaccine platforms. Three major platforms:
inactivated, subunit, and live attenuated/viral-vectored vaccines have been used to
generate a number of vaccine candidates for preclinical and clinical testing. A variety of
approaches and immunogens as shown were used. MV, measles virus; Ad, adenovirus;
VSV, vesicular stomatitis virus; VV, vaccinia virus. The figure is reproduced from
Pattnaik, A. et al., (2020).
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proteins, the mutant viruses were attenuated, induced robust neutralizing antibody
responses as well as T cell responses and conferred protection in immunocompromised
mice (Annamalai et al., 2019; Annamalai et al., 2017).
Chimeric DENV serotype 2 and JEV-encoding ZIKV prM-E proteins in place of
their corresponding proteins, have also been shown to protect mice and NHPs from ZIKV
challenge as well as from placental and fetal damage (Li et al., 2018a; Xie et al., 2017).
Perhaps the most interesting live attenuated chimeric ZIKV vaccine candidate that has
entered phase I clinical trials (NCT03611946) is the chimeric vaccine generated using the
backbone of DENV serotype 4 that expresses the prM-E proteins of ZIKV. This live
chimeric vaccine candidate, rZIKV/D430-713, contains a 30-nucleotide deletion in the
3’-UTR of DENV genome that results in reduced replication and significant attenuation
in NHPs and humans. One of the major challenges for an efficacious ZIKV chimeric
vaccine based on DENV or JEV as genomic backbones is the presence of pre-existing
immunity against these flaviviruses. Since there are cross-reactive antibodies in flavivirus
endemic areas, it is possible that these antibodies could inhibit or alter the immune
responses elicited by a flavivirus-based chimeric ZIKV vaccine. Additionally, as
discussed above, such pre-existing antibodies could also enhance vaccine-mediated
pathogenicity, possibly via ADE.

1.9.2. Vaccines employing other recombinant viral vectors
Replication-competent or -defective viral vectors expressing the prM-E genes of
ZIKV have also been developed as vaccine candidates. These include vesicular stomatitis
virus (VSV), measles virus (MV), vaccinia virus, and adenovirus (Ad). Attenuated
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versions of a recombinant VSV and measles virus expressing the prM-E of ZIKV
protected ZIKV challenged mice and NHPs (Betancourt et al., 2017; Nurnberger et al.,
2019). A vaccinia virus-based single vector construct expressing prM-E of ZIKV and the
structural proteins of chikungunya virus (C-E3-E2-6K-E1) induced neutralizing antibody
responses to both viruses in immunocompetent and immunocompromised mice and
blocked viremia and ZIKV vertical transmission (Prow et al., 2018). Several adenovirus
vectors expressing prM-E and/or E alone have also been developed and shown promise
as potential vaccines for ZIKV (Abbink et al., 2016; Abbink et al., 2017; Bullard et al.,
2018; Guo et al., 2018; Hassan et al., 2019; Larocca et al., 2016; Xu et al., 2018).

1.9.3. Virus-like particle (VLP) vaccines and subunit protein vaccines
VLP containing ZIKV prM-E have been generated in various expression systems
and examined for their ability to induce neutralizing antibody response as well as cellular
immune responses. The DNA- and RNA-based vaccines and recombinant viral vectors
described above generated VLPs directly in the animals for the induction of a protective
immune response. However, the use of various expression systems to generate and purify
the VLPs for administration into animals has advantages in that the animals respond to
only the viral antigens without any other components. Several such vaccine candidates
have been tested in preclinical studies and shown to induce neutralizing antibody and
cellular immune responses (Boigard et al., 2017; Dai et al., 2018; Espinosa et al., 2018;
Garg et al., 2020) and protect immunocompromised mice against lethal virus challenge
(Espinosa et al., 2018). In an attempt to avoid antibody dependent enhancement (ADE),
several groups have developed subunit vaccines by expressing only the domain III
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(EDIII) of the E protein. Such vaccine candidates have been shown to elicit neutralizing
antibody response in immunocompetent mice and sera obtained from such animals were
able to neutralize ZIKV in vitro (Yang et al., 2017a). In another study, the modification
of EDIII protein to shield a non-neutralizing epitope induced significantly higher
neutralizing antibodies in mice and fully protected pregnant mice and their fetus against
lethal challenge (Tai et al., 2019).

1.10. Recent developments in antiviral drugs
With the explosion of ZIKV cases in the Americas in 2016 and its association
with neurological and congenital diseases, intense efforts were made towards the
development of a number of drug candidates that could be tested in preclinical and
clinical trials. So far, a wide range of drugs targeting different steps of ZIKV lifecycle
have been shown to effectively inhibit the virus in vitro and in vivo. Upon infection of
cells, ZIKV goes through a series of steps to produce infectious progeny virions. This
multistep process starts with the virus attachment to the cell surface receptor and ends
with release of mature infectious virus particles. Thus, several inhibitors targeting
different steps of the virus lifecycle have been explored as potential antivirals.

1.10.1. Inhibitors and drugs targeting the viral proteins
The interaction of ZIKV E protein with cell surface receptors like Axl, TIM1, and
others is the first step in the infection process, and several drugs have been studied that
target this interaction (Jemielity et al., 2013; Meertens et al., 2017; Wells et al., 2016).
Several natural compounds such as EGCG (a polyphenol present in green tea), Curcumin
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(the active ingredient of turmeric) and Nanchangmycin (an antibiotic obtained from
Streptomyces nanchangensis) have been shown to inhibit the interaction of ZIKV E
protein with cellular receptors thereby inhibiting its internalization into host cells
(Carneiro et al., 2016; Mounce et al., 2017; Rausch et al., 2017). Additionally, the
chemical compound ZINC33683341, Chloroquine (a FDA-approved antimalarial drug),
Suramin (an anti-parasitic drug) have been reported to prevent virus infection in host
cells by a similar mechanism (Albulescu et al., 2017; Fernando et al., 2016; Li et al.,
2017).
ZIKV NS2B-NS3 are critical components of a ‘two protease system’ that is
essential for viral replication and maturation (Kang et al., 2017). Various synthetic
compounds such as CN-716 (a boronic acid containing dipeptide), AMPB (5-amino-1((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-yl ben-zoate) as well as the broad spectrum
serine protease inhibitor, Aprotinin, have been shown to strongly inhibit the protease
activity of ZIKV NS2B-NS3 that leads to inhibition of virus replication (Chen et al.,
2016; Lei et al., 2016; Li et al., 2018b; Shiryaev et al., 2017). Furthermore, several
polyphenol-based compounds (such as myricetin, picatechin gallate, astragalin, etc.),
metallopeptides, and novobiocin (am anti-bacterial drug) have also been reported to
target ZIKV NS2B-NS3 and suppress virus replication (Bernatchez et al., 2020).
ZIKV NS5 also serves as an ideal target for the development of antiviral drugs.
NS5 has both RdRp and methyltransferase activities and several drugs have been
demonstrated to inhibit virus replication by directly targeting it. Adenosine analogues
NITD008 and 7DMA (7-deaza-2′-C-methyladenosine) have been shown to potently
suppress ZIKV replication in cultured cells and reduce viremia and mortality in
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immunocompromised mice (Deng et al., 2016; Zmurko et al., 2016). Interestingly, the
clinically approved HCV inhibitor, Sofosbuvir and the broad spectrum inhibitor,
Galidesivir, have been tested in pregnant women and are shown to reduce disease
severity and prevent vertical and sexual transmission of ZIKV (Bernatchez et al., 2020;
Ferreira et al., 2017; Julander et al., 2017; Mesci et al., 2018; Mumtaz et al., 2017).
Additionally, non-nucleoside RdRp inhibitors have also been reported that allosterically
bind to the polymerase active site and interfere with nucleotide incorporation and reduce
viral load in mice (Pattnaik et al., 2018).
In addition to the above mentioned classes of inhibitors, several other compounds
have been described that suppress ZIKV replication by interfering with viral fusion with
autophagosomal membranes, viral assembly, and nucleoside biosynthesis (Bernatchez et
al., 2020; Boldescu et al., 2017; Delvecchio et al., 2016; Li et al., 2017).

1.10.2. Inhibitors and drugs targeting the viral genomes that form G-quadruplex
structures
The guanine (G)-rich regions in DNA and RNA sequences can fold into fourstranded, right-handed helical structures resulting in the formation of non-canonical
secondary structures in which the strands are stabilized by Hoogsteen hydrogen-bonded
four guanine bases to form a planar G-quartet or G-tetrad (Gellert et al., 1962;
Sasisekharan et al., 1975; Zimmerman et al., 1975). The Hoogsteen hydrogen bonds are
formed between N7 groups of one guanine with the exocyclic amino group of the
neighboring guanine, leading to planar association of four guanines that are held together
by eight such hydrogen bonds to form the G-quartet (Fig. 1.5 A). Stacking of two or more
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Fig. 1.5. G-Quadruplex structure. (A) Four Hoogsteen hydrogen-bonded guanosine
residues form a planar structure called G-quartet with a metal ion (M+). Stacking of two
or more such G-quartets results in G-quadruplex structures of parallel (B), antiparallel
(C), and mixed (D) topologies.
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of such G-quartets upon each other can be stabilized by monovalent cations such as K+
and Na+ that are centrally coordinated to O6 atoms of the guanines resulting in the
formation of G-quadruplex structures (GQs) (Sen and Gilbert, 1990). Depending upon
the sequence of the G-rich regions in the nucleic acids, the structure of the GQs can be
highly polymorphic and diverse. The GQs can be formed with one strand of DNA or
RNA (intramolecular) or can be formed from two or four separate strands of nucleic acids
(intermolecular). Additionally, the topology (parallel, antiparallel, or mixed; Fig. 1.5 BD), stability, and the dynamics of the GQs appear to be determined by a number of
factors including the conformational state of the glycosidic linkage (anti or syn) between
the guanine base and the sugar moiety, number of G tetrads, loop length and sequence
composition, directionality of the strands, molecular crowding, etc. (Arora et al., 2009;
Burge et al., 2006; Cheng et al., 2018; Guedin et al., 2008; Qin and Hurley, 2008;
Sahakyan et al., 2017; Sattin et al., 2013; Shrestha et al., 2017).
A large body of literature over the past two decades suggest that the GQs play
crucial regulatory roles in a number of biological processes such as DNA replication,
repair, transcription, translation, telomere maintenance, meiosis, etc. (Biffi et al., 2013;
Eddy and Maizels, 2006; Eddy et al., 2011; Rhodes and Lipps, 2015; Sen and Gilbert,
1988). Genome-wide analyses have revealed the prevalent existence of GQ-forming
sequences as conserved cis-acting regulatory elements in human and other eukaryotic
genomes (Bedrat et al., 2016; Huppert and Balasubramanian, 2005; Verma et al., 2008)
and that such sequences play important roles in biological processes involving DNA and
RNA (Du et al., 2008; Maizels and Gray, 2013; Rhodes and Lipps, 2015; Verma et al.,
2008). Over the years, considerable attention has been directed at developing search
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engines, analysis tools, and algorithms to predict the presence of GQs in the genomes of
living organisms. With the development of sophisticated algorithms and analysis tools,
the GQs have been predicted to exist in prokaryotes, eukaryotes, as well as in viruses,
parasites, and fungi. In general, to search for GQ structures predictive models use the
consensus sequence motif of four runs of at least three guanines separated by one to
seven short stretches (loops) of any of the four nucleotides (5’ G3+N1-7G3+N17G3+N1-7G3+ 3’ where N is any nucleotide) (Huppert and Balasubramanian, 2005;
Todd et al., 2005), although prediction for less stable GQ structures with variations in
loop length, discontinuities in G-stretches or GQs with only two tetrads have been
incorporated in some algorithms. Furthermore, methods have been developed to
experimentally detect and map GQ structures in the genomes of model organisms
including human, mouse, and several pathogens (Chambers et al., 2015; Marsico et al.,
2019). Overall, the data from these studies reveal that the locations of the observed GQs
are not random, particularly in human and mouse; rather, they are enriched in gene
regulatory regions such as in the promoter regions and transcription start sites of many
cellular genes and oncogenes as well as in repetitive regions such as telomeres. These
studies support the prediction from computational and cellular analysis of human genome
for potential regulatory roles of GQs (De and Michor, 2011; Hansel-Hertsch et al., 2016).
The GQ-forming sequences have also been predicted to be present in the genomes
of all known human viruses (Lavezzo et al., 2018) including recently emerged ZIKV
(Fleming et al., 2016), SARS-CoV-2 (Cui and Zhang, 2020). As a result, studies in recent
years have focused on the possibility of using these GQ structures as antiviral targets. In
support of this possibility, ligands such as Braco-19, TMPyP4, pyridostatin (PDS), etc.
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that specifically bind and stabilize GQ structures have been shown to inhibit replication
of a number of viruses such as human immunodeficiency virus 1 (Butovskaya et al.,
2019), hepatitis C virus (Wang et al., 2016a), Ebola virus (Wang et al., 2016b), etc.
Therefore, it is likely that GQ-binding and -stabilizing ligands could be used to inhibit
ZIKV replication.

1.11. Hypotheses and objectives in this doctoral thesis
The recent reemergence and large-scale spread of ZIKV and its association with
serious neurological disorders, necessitates the development of antiviral countermeasures
for the prevention and treatment of ZIKV infections. With no vaccines or antiviral drugs
approved for use against ZIKV infections, there is an urgent need to explore strategies to
develop viral countermeasures such as established vaccine platforms and drug repurposing efforts. Alternative strategies such as use of innovative vaccine platforms,
screening for small molecule chemical libraries based on their ability to specifically bind
viral macromolecules and inhibit viral replication should also be investigated. In recent
years, ferritin-based nanoparticles have been used to develop vaccine candidates for a
number of viruses. Presentation of multiple copies of an antigen in a repetitive array
exemplified by formation of multivalent nanoparticles or nanocages can theoretically
induce more potent and long-lived humoral immune responses than the soluble antigen
(Lopez-Sagaseta et al., 2016). Based on this premise, we hypothesize that ferritin
nanoparticles (or nanocages) displaying multiple copies of the DIII domain of ZIKV
will produce robust neutralizing antibody responses that will protect the animals from
lethal challenge with ZIKV. Ferritin nanoparticles self-assemble from 24 subunits
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(molecules) into a soccer ball-like structure. Therefore, in one of the objectives of this
thesis, we propose experiments to test this hypothesis. A second objective of my thesis is
to identify and characterize small molecule inhibitor(s) that target the ZIKV RdRp. Using
DENV RdRp as a template, we predicted the structure of ZIKV RdRp which was used for
in silico screening of a library of compounds. We identified a number of small molecule
non-nucleoside compounds, including 3-chloro-N-[((4-[4-(2-thienylcarbonyl)-1
piperazinyl]phenyl)amino) carbonothioyl]-1-benzothiophene-2-carboxamide (TPB) that
specifically target the catalytic cavity of the RdRp. We hypothesize that TPB will inhibit
ZIKV replication both in vitro and in vivo and protect animals from ZIKV-induced
diseases. A third objective of my thesis is to test if drugs and compounds that
specifically bind to ZIKV genome would inhibit viral replication and infectious progeny
production. This objective is developed based on the recent in silico analysis of several
ZIKV strains that predicted the presence of non-canonical secondary structures called Gquadruplexes (GQs) in the viral genome. We hypothesize that ligands that bind and
stabilize GQ structures in ZIKV genome will inhibit virus replication and progeny
production. We have proposed and conducted studies to test this hypothesis and achieve
the objective.
Overall, my thesis presents a set of hypotheses, and the following objectives are
developed to test these hypotheses.

1.11.1. Construction and characterization of a nanoparticle based vaccine candidate
against ZIKV infection.
The studies and results of this objective are described in chapter III.
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1.11.2. Identification and characterization of a non-nucleoside inhibitor of ZIKV
RNA polymerase.
The studies and results of this objective are described in chapter IV.

1.11.3. Investigation of ZIKV replication in the presence of G-quadruplex binding
ligands.
The studies and results of this objective are reported in chapter V.
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CHAPTER II: MATERIALS AND METHODS

2.1. Cell culture
Vero (Cercopithecus aethiops, CCL-81), HEK293T (CRL-3216), HTR-8/SVneo
human trophoblast (CRL-3271), SH-SY5Y human neuroblastoma (CRL-2266) and
NTERA-2 human embryonal carcinoma (CRL-1973) cells were obtained from ATCC.
The cells were grown and maintained in Dulbecco's modified Eagle's medium (DMEM)
containing 10% heat-inactivated fetal bovine serum (FBS) and 1X
penicillin/streptomycin (PS) solution (complete growth medium) in a humidified
incubator with 5% CO2 at 37 °C. 293-F cells (Cat# R79007) were obtained from
ThermoFisher Scientifc and were grown in FreeStyle™ 293 Expression Medium (Cat#
12338018). The cells were grown in sterile conical flasks on a shaker (at 140 rpm) in a
humidified incubator with 8% CO2 at 37 °C.

2.2. ZIKV stock preparation
ZIKV strain PRVABC59 and MR766 were obtained from Barbara Johnson and
Brandy Russell at the Centers for Disease Control and Prevention, Fort Collins,
Colorado, USA. The viruses were passaged once in Vero cells to prepare stocks. Briefly,
24 hours prior to the infection, Vero cells were set up in a T-75 cell culture flask and
allowed to grow to about 90% confluency. Cells were washed with phosphate buffered
saline (PBS) followed by infection with either PRVABC59 or MR766 virus at a
multiplicity of infection (MOI) of 0.1. For virus adsorption, cells were incubated at 37° C
for 1 hour with intermittent shaking every 15 mins to prevent the cell monolayer from
drying. The monolayer was then washed with PBS and virus growth medium (VGM)
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[DMEM containing 2%FBS, 1X PS, 20 mM hydroxyethyl piperazine ethane sulfonic
acid (HEPES), 1 mM sodium pyruvate, and 1X non-essential amino acids] was added.
The infected cells were monitored for the development of cytopathic effect (CPE) and on
day four post infection, the culture supernatant was harvested and clarified by
centrifugation (20000xg) for 10 minutes at 4°C. Small aliquots were made and stored at 80° C until use.

2.3. Plasmids
The plasmid vector pIRES-2-eGFP was obtained from Addgene (Watertown,
MA). The expression cassette encoding the soluble ZIKV (MR766) E protein (solE) and
H. pylori ferritin, termed solE-F was cloned into a pUC57 cloning vector backbone
(pUC57-solE-F), commercially synthesized, and obtained from Genscript (Piscataway,
NJ). The expression cassette for solE-F was designed keeping restriction sites, coding
sequences for ZIKV E, ferritin, and other elements in the following order: NheI, Kozak
sequence, Secrecon signal sequence (includes the initiation codon), SmaI/XmaI, solE,
linker sequence (aa Ser-Gly-Gly: creating a BspEI restriction site), ferritin, stop codon
and NotI. The expression cassette was codon optimized prior to gene synthesis for
efficient mammalian cell expression.

2.4. Recombinant DNA construction
2.4.1. DNA cloning
Using restriction sites, NheI and NotI, the expression cassette for solE-F (insert)
was digested from the pUC57 cloning vector and cloned into pIRES-2-eGFP expression
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vector. Digestion of pIRES-2-eGFP plasmid by NheI and NotI releases a fragment that
includes the coding sequence for eGFP (vector) (Fig 3.2A). For the replacement of the
consensus secrecon signal sequence with tPA or µ-phosphatase signal sequence, primer
combinations A_F and C_R or B_F and C_R (Table 2.1) along with pUC57-solE-F as the
template was used to generate DNA fragments encoding tPA or µ-phosphatase signal
sequence. For the generation of zDIII-F expression cassette, the solE fragment was
replaced with PCR amplified DNA fragment encoding zDIII using primers D_F and C_R
(Table 2.1). Q5® High-Fidelity PCR Kit was used for PCR amplification of the DNA
fragments. Briefly, a 30 μl reaction mixture contained 15 μl of the Q5 High-Fidelity 2X
Master Mix , 1.5 μl (10 μM) each of forward and reverse primers , 1 μl (100 ng/ μl)
plasmid DNA template, and 11 μl nuclease-free water (NFW). The PCR cycling
conditions were: 1 cycle of 98°C for 30 sec, 35 cycles of 98°C for 10 sec, 58°C for 30 sec
and 72°C for 80 sec (depending on fragment size, 40 sec/kb), 1 cycle of final extension at
72°C for 5 min. The PCR amplified fragments were digested with NheI/XmaI and NotI
and separated in a 0.8% agarose gel. The DNA fragments were extracted from the gel
using a gel purification kit from Thermo Scientific (Cat# K0961) and were subsequently
used for ligation in the into pIRES-2-eGFP vector.

2.4.2. DNA ligation
For DNA ligation, a mixture of restriction digested vector and insert fragments in
a total volume of 8μl was taken in a microfuge tube followed by the addition of 1 μl T4
ligase buffer (10X) and 1 μl T4 DNA ligase (NEB Cat# M0202S). The mixture was
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incubated at room temperature for 4 hr. The ligation mixture was heat inactivated at 65°C
for 10 min and chilled on ice before bacterial transformation.

2.4.3. Bacterial transformation
Three μl of the heat inactivated ligation mix was added to 50 μl of competent E.
coli DH5α bacterial cells followed by incubation for 30 min on ice. The bacterial cells
were heat-shocked at 42°C for 90 sec followed by incubation for 5 min on ice. The
transformed bacterial cells were re-suspended in 1ml of LB broth incubated at 37°C for 1
hr in a shaker (230 rpm). This was followed by finally, plating on LB agar plates
containing Kanamycin (50 ug/ml) for selection of kanamycin resistant clones.

2.4.4. Clone screening and large scale plasmid preparation
Kanamycin resistant bacterial colonies were picked and cultured overnight at
37°C in LB medium containing Kanamycin. Miniprep plasmid extraction was done
followed by restriction digestion with appropriate enzymes to confirm bacterial clones
containing the expression cassette. Briefly, cultured bacterial cells were pelleted and
lysed in 300μl of TENS buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1 M NaOH,
0.5% SDS). The above mixture was neutralized by adding 150 μl of sodium acetate (pH
5.2), was centrifuged and the supernatant was transferred to a new centrifuge tube. For
precipitation of plasmid DNA, 2.5 volumes of cold 100% ethanol was added, and the
mixture was centrifuged at 13,200 rpm for 5 min. The DNA pellet was washed with cold
(-20⁰C) 70% ethanol and air-dried. The dried plasmid DNA was resuspended in 30 μl of
Tris-EDTA buffer containing 100 μg/ml of RNaseA. The plasmid DNA was checked for
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sequence correctness using commercial DNA sequencing services. For large scale
plasmid preparation, Qiagen Plasmid Plus Maxi Kit (Cat# 12963) was used. Briefly,
bacteria containing the correct plasmid DNA were grown in 500 ml LB medium
containing kanamycin. The bacterial cells were pelleted at 6000xg for 15 mins at 4⁰C.
this was followed by plasmid DNA extraction following the protocol outlined in the kit
manual.

2.5. Plasmid transfection and protein expression
HEK293T cells were seeded in a 6-well plate and allowed to grow till ~70%
confluency. Plasmid DNA encoding for solE-F or zDIII-F (1 and 2.5 μg) were transfected
using Lipofectamine 2000 (Thermo Fisher Cat# 11668027) following manufacturer
recommended protocol. Briefly, DNA Lipofectamine mixture was made using the ratio
1:4 in OptiMEM (Thermo Fisher Cat# 31985062) and incubated at RT for 20 mins to
facilitate the formation of DNA lipid complexes. Cells were washed with 1X PBS and
250 μl of OptiMEM was added to the monolayer followed by the dropwise addition of an
equal volume of the DNA Lipofectamine mixture. The cells were incubated at 37 °C, 5%
CO2 for 6 hr following which the cells were washed with 1X PBS and replenished with
complete growth medium and incubated for 2-5 days. For large scale production (500ml)
of zDIII-F, 293F cells were seeded at a density of 5-7 x 105 cells per ml the day prior to
transfection. The following day, the cells were checked for viability using trypan blue
dye exclusion assay. DNA transfection was done if the cells were 90% viable and the
cell density was ~1 x 106 cells per ml. For DNA transfection, plasmid DNA at 1 g per 1
million cells was mixed with appropriate volume of OptiMEM containing 293Fectin/PEI
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(Thermo Fisher Cat# 12347019). The DNA and 293Fectin mixture (1:4) was incubated at
RT for 20 mins to facilitate the formation of DNA lipid complexes and was added to the
cells. The cells were incubated for 4 days on a shaking platform following which they
were pelleted at 8000xg for 20 mins at 4⁰C. Cell pellets and the clarified culture medium
were checked for protein expression as described below by SDS-PAGE and Western
blotting.

2.6. zDIII-F protein purification
The clarified culture medium was filtered through a 0.2 m filter and buffer
exchanged with TN50 buffer containing 20 mM Tris pH 7.5, 50 mM NaCl. The buffer
exchange was done using a tangential flow filtration system with a Pellicon® 2 Mini
Cassette with an Ultracel® 30 kDa Membrane (Millipore). Protein was then purified
from this buffer exchanged media using a 5 ml HiTrap Q FF column (GE Healthcare) and
an ÄKTApure system (GE Healthcare). The column was rinsed with 10 CV of TN50
buffer, and then a 20 CV elution gradient from 50-1000 mM NaCl was utilized for
elution of the protein. Peak fractions were tested for the presence of the protein by SDSPAGE, and fractions containing the ZDIII-F protein were pooled and concentrated using
a Amicon Ultra centrifugal filter unit with a 100 kDa cut off (Millipore). This was
followed by separation of the pooled fractions by size exclusion chromatography (SEC)
using a Superdex 200 16/600 pg column (GE healthcare). The elution of the purified
protein was done in PBS and fractions were examined by SDS-PAGE. The eluted protein
fractions were stored at -80⁰C until use. For thermostability analysis, several aliquots of
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the purified zDIII-F protein were stored at 4⁰C for the indicated lengths of time (refer to
Fig. 3.6 C and D)

2.7. SDS-PAGE and gel staining
Elution fractions from ion exchange and size exclusion chromatography were
subjected to SDS-PAGE analysis to determine the presence of the purified protein.
Protein estimation was done by determining the absorbance at 280 nm with 1 absorbance
unit corresponding to 1 mg/ml protein. Briefly, ~1 g of protein from each fraction was
loaded per well on a 4-12% precast polyacrylamide gel and electrophoresed at 200 V for
30 mins. After electrophoresis, the gels were stained with either SimplyBlue SafeStain
(Novex Biologicals) for 20 mins or Oriole fluorescent gel stain (BioRad) for 90 mins.
Following staining, the gels were washed with deionized water and imaged using a
Biorad gel imager.

2.8. Western blotting
For the detection of solE-F, zDIII-F and ZIKV E proteins, western blotting
analysis was performed as described (Sahoo et al., 2020). For the preparation of cell
lysates, cells were washed with cold PBS, trypsinized, and harvested by pelleting at
500xg for 5 min at 4°C. The cell pellet was resuspended in radio-immunoprecipitation
assay (RIPA) buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS) supplemented with the protease and phosphatase
inhibitor cocktail and incubated on ice for 15 min with intermittent vortexing after which
the lysates were clarified by centrifugation at 10,000xg for 5 min, 4° C. Total protein
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quantification was done using the bicinchoninic acid (BCA) assay kit (Thermo Fisher).
Twenty g of total protein was separated by electrophoresis as described (section 2.7).
The separated proteins were transferred onto polyvinylidene difluoride (PVDF)
membranes using a Bio-Rad semi-dry transfer system and blocked with 5% non-fat milk
in 1X tris-buffered saline (TBS) containing 0.2% Tween 20 (TBS-T). The membranes
were incubated with primary antibody against respective proteins: anti-ZIKV E (Genetex
Cat # GTX1333325) and anti-ZIKV E DIII (ZV-57; monoclonal antibody obtained from
Michael S. Diamond, School of Medicine, Washington University, St. Louis). The
primary antibodies were used at a dilution of 1:1,000 in 5% non-fat milk in TBS-T and
the membranes were incubated at 4⁰C overnight. The membrane was washed three times
in TBS-T and incubated for 2 hours at room temperature with HRP-conjugated secondary
antibodies, either goat anti-rabbit (Sigma Cat # A6154) or goat anti-mouse (Sigma Cat#
12-349) at a dilution of 1:10,000, in 5% non-fat milk in TBS-T. The membrane was
washed three times in TBS-T and bands were detected using enhanced chemiluminescence (ECL) western blotting substrate (Biorad cat # 1705061) using a Biorad
imager.

2.9. Transmission electron microscopy (TEM) imaging of zDIII-F nanoparticles
A 30 ul (100ng/l) droplet of purified zDIII-F was placed on parafilm and the
surface of a carbon-formvar coated copper grid was placed upside down to contact the
samples for 1-2 min. After excess specimen was wicked away by touching a piece of
filter paper to the edge of the grid surface, the grid with the sample side up was air-dried
for ~2 min. The grid was placed upside down on to a drop (30 ul) of 1% phosphotungstic
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acid solution for ~2 min. Excess stain solution was wicked from the grid following the
staining and air-dried for at least 30 min. Samples were examined and different
magnifications of images were collected using a Hitachi H7500 TEM (at 80 KV).

2.10. Molecular modeling and in silico screening
The ZIKV RdRp structure was modeled based on sequence homology using the
DENV-3 RdRp structure (PDB: 2J7U) (Yap et al., 2007) as a template in Modeller 9
program (Webb and Sali, 2014). In silico screening was performed using Molegro Virtual
Docker (MVD) software (Molegro ApS, Aarhus, Denmark). The docking site was
defined using a ray-tracing algorithm. This resulted in a cavity with a volume of
approximately 1034 cubic Å. A receptor grid was built within this cavity with a
resolution of 0.2 Å and a radius of 13 Å from the geometric center of the cavity in the
ZIKV RdRp model. Structure based docking was done using a library of 100,000
compounds from ChemBridge (Chembridge DIVERSet™ Chemical Library,
ChemBridge Corporation, San Diego, California) and the top 10 compounds were
selected based on docking scores for experimental validation. All structural modelling
and analysis were conducted in the Discovery Studio 4.0 (Biovia, San Diego, CA).

2.11. Preparation of stocks of ZIKV inhibitors
Ten lead compounds (Table 4.1) were purchased from Hit2Lead Company
(ChemBridge Corporation, San Diego, California). Each compound was dissolved in
dimethyl sulfoxide (DMSO) to prepare stock solutions of 10 mM and 1 mM and was
stored at -20⁰ C. The compound 1 (c1) used in this study is 3-chloro-N-[((4-[4-(2-
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thienylcarbonyl)-1-piperazinyl]phenyl)mino)carbonothioyl]-1-benzothiophene-2carboxamide (TPB). Based on 1H NMR and LC-MS (ELSD, DAD 200–400 nm, MSD
APCI positive) analyses by the provider, the compound is ≥ 95% pure. Mycophenolic
acid (MPA) and Ivermectin (IVM) were purchased from Sigma (St. Louis, MO) and
resuspended in DMSO to prepare stock solutions. All the compounds used have ≥ 95%
purity. Small-molecule ligands, Braco-19 and TMPyP4, were purchased from Sigma,
dissolved in water and DMSO, respectively, for preparation of stock solutions, and stored
at -20⁰ C until further use.

2.12. Prediction of putative G-quadruplex (GQ)-forming sequences from the ZIKV
genome
A total of 247 complete genome sequences of ZIKV were retrieved from the
NCBI Genome database (https://www.ncbi.nlm.nih.gov/genomes). The FASTA
sequences of the ZIKV genomes were then used for the prediction of the putative GQforming sequences with the help of in-house GQ prediction tool (Lim et al, 2017). The
search was based on the following algorithm: G≥2N1-7G≥2N1-7G≥2N1-7 G≥2 where G
corresponds to guanine and N corresponds to any base including guanine. Though the
ZIKV is a positive-sense RNA virus, we also sought to find the probable GQ sequences
in the anti-sense strand of the viral genome. Further, the consensus sequences for each of
the ZIKV GQs studied were generated using the WebLogo software (Crooks et al, 2004).

2.13. Plaque assay
Virus stock titration was performed by plaque assay using Vero cells as described
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in Annamalai et al, 2017. One day before the assay, cells were plated on a 12 well plate
at a density of 2x 105 cells per well. On the assay day, cells became 90-100% confluent.
Serial 10-fold dilutions of virus stock were prepared using VGM and kept on ice. The cell
monolayer was washed with 1X PBS and 100 l of each dilution was added to the
monolayer. Virus adsorption was done as described above. Following the virus
adsorption, the inoculum was removed, the cell monolayer was washed with 1X PBS and
overlaid with 1ml of a 1:1 ratio of 2% low gelling temperature (LGT) agarose (w/v) in
water and 2X VGM. After a 5 day incubation at 37°C, the cells were fixed in 10%
formaldehyde in 1X PBS for 30 minutes, the agarose plugs were removed, and the
monolayers were stained with 0.1% crystal violet in 30% methanol in water. Excess
staining solution was washed with water and the plaques were counted manually and
expressed as PFU/ml.

2.14. Plaque reduction neutralization (PRNT) test
Vero cells were seeded in 12 well plates 1 day prior to the assay to have a
confluency of 90-100% at the time of infection. Serum samples obtained from control
and zDIII-F immunized mice at 28 days post vaccination were heat inactivated at 56°C
for 30 min. The sera were diluted 1/100 followed by serial 1/2 dilutions. A 50 µl volume
containing ~200 plaque-forming units
(PFU) of ZIKV (rMR, PRVABC59 or MEX1-7) was mixed with an equal volume of
diluted serum sample and incubated at 37°C for 1 hr. After incubation, the mixture was
applied to Vero cell monolayers and the cells were incubated at 37°C for 1 hr with
intermittent shaking every 15 min. After the incubation, the inoculum was discarded and
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the cells were overlayed with 1 ml of 1% LGT agarose in VGM and incubated for 5 days
at 37⁰C in a humidified CO2 incubator. The cells were fixed using 10% formaldehyde in
PBS for 30 min and the agarose overlays were removed. The cell monolayers were
stained with 0.1% crystal violet in 30% methanol. Plaques were counted manually, and
antibody titer was determined as the reciprocal of the serum dilution that inhibited 50%
of the infectivity (PRNT50).

2.15. Virus inhibition assay
Virus inhibition assays were performed in two ways. In the first approach, Vero
cells were seeded in a 96-well plate at a density of 6000 cells per well. A mixture of the
compound (1 μM) and the virus (0.1 PFU/cell) was made in VGM and was added to the
cells. The cells were incubated for 72 hr at 37⁰ C in a humidified incubator containing 5%
CO2. In a separate experiment, Vero cells were seeded in a 12 well plate at a density of
40,000 cells per well and were infected with the virus at MOI 0.1 and following
adsorption, the cells were washed twice in 1X PBS and incubated in VGM containing 1
μM concentrations of the drugs. The cell culture media were collected at 96 hr postinfection and assayed for infectious virus yield by plaque assay. Viral genome copies
were determined by quantitative RT-PCR (qRT-PCR). In all subsequent studies, cells in
12-well plates were infected with ZIKV at an MOI of 0.1 PFU/cell and following virus
adsorption for 1 h at 37⁰ C, VGM containing various concentrations TPB was added to
the cells and incubated as above. Clarified supernatants from the infected cells were then
used to determine infectious virus or genome copies as above.
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To assess the effect of GQ binding ligands, Braco-19 or TMPyP4, on ZIKV
replication, Vero cells were infected with the virus at an MOI of 1. Following adsorption
at 37⁰ C for 1 hr, the inoculum was removed and replaced with VGM containing various
concentrations of Braco-19 or TMPyP4. Infected cells were incubated at 37⁰ C and small
aliquots of infected cell culture supernatants were collected every 24 hr post infection
(hpi) till 96 hpi, clarified, and stored at -80⁰ C for virus titration at a later time. To
determine the amount of cell-associated infectious virus, after collecting culture
supernatants, the cells were subjected to two cycles of freeze-thaw at -80⁰ C in the
presence of the same volume of growth medium followed by centrifugation at 20,000xg
for 10 min at 4⁰ C. The clarified supernatants were then used to quantify the cellassociated virus by plaque assay.

2.16. Quantitative real time RT-PCR
ZIKV viral RNA was detected using qRT-PCR on a C100 Thermal Cycler and the
CFX96 Real-Time system (Bio-Rad). Viral RNA (vRNA) was extracted from culture
supernatant, sera, or tissue samples from infected mice using a QIAamp Viral RNA Mini
kit (Qiagen). Tissue samples were homogenized using metal beads in 1X DMEM in
Bullet Blender® (Next Advance, Inc., New York) with a speed setting of 10 for 5 min at
4⁰C. This was followed by clarification of the homogenized tissues by centrifugation at
14,000xg for 15 min at 4⁰C and the clarified supernatants were used for viral RNA
isolation. TaqMan Fast Virus 1-Step Master Mix (Life technologies) was used, and the
determination of viral genome copies was done following manufacturer’s
recommendation. ZIKV primers and probe used are as follows (ZIKV_F:
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CCGCTGCCCAACACAAG; ZIKV_R: CCACTAACGTTCTTTTGCAGACAT; PCR
Probe: ZIKV-P: AGCCTACCTTGACAAGCAATCAGACACTCAA). The cycling
conditions used were: 50°C for 30 min, and 95°C for 5 min followed by 40 cycles of
95°C for 30 secs, and 58°C for 1min. RNA standard concentrations were determined
based on the back calculation with OD values and molecular weights and were generated
through serial dilution with R2 > 0.95.
For the GQ binding ligands studies, total RNA from infected cells at 72 or 96 hpi
were isolated using TRIzol RNA isolation reagent (Thermo Fisher Scientific) and viral
genomic copy numbers were determined using specific probes and primers. The forward
primer (5’-GTC GTTGCCCAACACAAG-3’) and the reverse primer (5’-CCAC
TAATGTTCTTTTGCAGAC-3’) along with the fluorescent probe 5’ -/56-FAM (5’ -6carboxyfluorescein)/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/3IABkF
Q (3’ -Iowa black fluorescent quencher)/-30 were used to determine the standard curve
with an oligonucleotide template spanning E gene sequences at positions 1191to 1268.
The real-time PCR assays involved two steps. The first step included the cDNA synthesis
from the viral RNA using the SuperScript II (Thermo Fisher Scientific, Waltham, MA,
USA). The synthesized cDNAs were then used as templates in the qPCR. The qPCR
cycling conditions used were as follows: initial denaturation at 95⁰ C for 10 mins; 35
cycles of 95⁰ C for 30 s, 55.3⁰ C for 30 s, and 72⁰ C for 30 s; and a melt curve from 65⁰ C
to 95⁰ C with 0.5⁰ C increments for 5 secs. The reactions were run in CFX Connect
instrument (Bio-Rad, Hercules, CA, USA). Viral-genome copy numbers were determined
in parallel reactions using RNA samples in duplicate and expressed as copy numbers per
mg of total cellular RNA and expressed as log10 copies per µg of total cellular RNA.
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2.17. ATP-based cell viability assay
A modified ATP based cytopathic effect (CPE) assay was used for this study
based on the CPE method for anti-DENV drug development described previously (Che et
al., 2009). Vero cells were seeded at a density of 30,000 cells per well in a black
bottomed 96-well plate 24 hr before the experiment. Cell monolayers were treated with
various concentrations of the drugs and incubated for 96 hr at 37⁰ C in a humidified
incubator containing 5% CO2. The ATP concentration was measured following
manufacturer's recommendations using CellTiter-Glo kit from Promega (Madison,
Wisconsin). Luminescence was recorded using a Veritas Microplate Luminometer at 420
nm. The 50% cytotoxic concentration (CC50) was calculated by a non-linear regression
analysis of the dose-response curves.

2.18. Determination of cell viability by flow cytometry
Vero cells were seeded in 12-well plates at a density of 20,000 cells per well.
They were left untreated or treated with 0, 1, 10 and 100 µM of Braco-19 or TMPyP4 and
incubated for 96 hrs. Cell culture supernatant was discarded and the cell monolayer was
washed with 1X PBS, trypsinized and pelleted at 500xg for 10 mins. The pellet was resuspended in staining solution containing propidium iodide (PI, 1 µg/ml, Sigma Aldrich,
P4170), and monochlorobimane (mBCl, 10 μM, Molecular Probes, M1381MP) in PBS
and incubated at room temperature for at least 20 mins. Cell viability was determined by
flow cytometry (FACS, Fluorescence Activated Cell Sorting) using Cytek-DxP-10 (BD
Biosciences). PI was detected using the BluYel FL-3 channel (488 nm excitation, 695/40
nm emission) and mBCl was detected using the VioFL1 channel (389 nm excitation and
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483 nm emission). 10,000 events were recorded, and dead cells were gated as mBCl
positive (-) and PI negative (+). The data analysis was done in FlowJo 7.6.5 software.

2.19. Mouse studies
2.19.1. ZDIII-F vaccination and challenge studies
Three-week old interferon (IFN) α/β receptor knockout mice (A129) were
purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and acclimatized for 4
days at the mouse facility at University of Nebraska-Lincoln. zDIII-F (10 g) in 100 µl of
PBS was mixed with 100 µl of Addavax (Invivogen Cat# vac-adx-10) and administered
in mice using a 22 gauge needle by the subcutaneous route. PBS was injected to mice in
the control group. Following this, the mice were observed daily till 28 days when they
were infected with ZIKV (rMR, 10,000 pfu/mouse) by the subcutaneous route. The mice
were kept under observation for the development of disease symptoms for 7-10 days
during which blood samples were drawn by retro-orbital puncture under anesthesia
(isoflurane treatment) on days 2, 4, and 6 post-infection for determination of viral
genome copies. For passive transfer experiment, 4-week old A129 mice were injected
intravenously with 200 l of naïve or zDIII-F immunized mice serum. Four hours later,
the mice were given a lethal dose of ZIKV (rMR, 10,000 pfu/mouse) and were monitored
for the development of disease symptoms for 7-10 days during which blood samples were
drawn by retro-orbital puncture on days 2, 4, and 6 post-infection for determination of
viral genome copies. Some animals were euthanized at day 4 post lethal challenge and
organs (brain, liver, and spleen) were harvested for determination of tissue viral load.
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2.19.2. Pharmacokinetic (PK) study
For PK studies, groups of Balb/C mice (n = 6) obtained from the Jackson
Laboratory (Bar Harbor, ME, USA) and acclimatized for four days were injected
intraperitoneally (IP) with doses of 5 mg/kg or 25 mg/kg of body weight of TPB in 5%
dextrose. The animals were bled under anesthesia (as described above) using the retroorbital route at every 2 hr and plasma was harvested and stored at -80° C. TPB
concentrations were analyzed by LC-MS/MS. Plasma drug levels were subjected to noncompartmental analysis (WinNonlin ver. 6.4 Certera Inc., Princeton, N.J.). The predicted
steady-state levels > 500 ng/ml were estimated using a 12 hr dosing at 25 mg/kg dose for
three doses of the compound in mice.

2.19.3. Viral inhibition test in mice
Four-week old Balb/C mice were obtained from the Jakson Laboratory (Bar
Harbor, ME, USA ). After acclimatization for four days, groups of animals (n = 6) were
injected IP with saline alone or 25 mg/kg body weight dose of TPB diluted in saline.
Following three injections at 12 hr intervals, the mice were infected with 500 PFU of
PRVABC59 virus diluted in 100 l 1X PBS by the subcutaneous (SC) route. Blood was
collected by retro-orbital bleeding under anesthesia on days 2, 3, 4, 5, and 6 post
infection. Viral genome copies in the plasma were determined by qRT-PCR.

2.20. Determination of drug concentration in plasma
TPB was dissolved in DMSO at 1 mg/ml. Working standard solutions were then
prepared in 50% methanol in water from the stock solution. Standards (an eight-point
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calibration curve) and quality controls (at three levels) were prepared by spiking the
working standard solutions to blank mouse plasma. One hundred microliter aliquot of
plasma was mixed with 25 μl of internal standard spiking solution (rilpivirine 1000 ng/ml
in 50% acetonitrile in water), 1.5 ml ethyl acetate was added and vortexed vigorously for
15 min. The tubes were centrifuged at 1700×g for 5 min and 1.3 ml supernatant was
evaporated to dryness under a stream of nitrogen at 40°C. The dried extract was
reconstituted with 0.1 ml of 50% acetonitrile in water and 5 μl was injected into the LCMS/MS instrument. The dynamic range of the method was 25–4000 ng/ml.
An Agilent 1200 HPLC system (Agilent Technologies, CA, USA) coupled with AB Sciex
API 3200 Q Trap with an electrospray ionization source (Applied Biosystems, Foster City,
CA, USA) was used. The mass transitions m/z 541.2 → 330.2 and 541.2 → 212.2 for
analyte and m/z 367.2 → 195.2 for internal standard were monitored. Chromatographic
separation was carried out on Phenomenex Synergi Polar-RP (150 × 2.0 mm, 4μ) column
with isocratic mobile phase consisting of 0.1% formic acid in water (A) and 0.1% formic
acid in acetonitrile (B) (20:80 v/v) at a flow rate of 0.5 ml/min. The retention times of
analyte and internal standard were 2 and 1.2 min respectively.

2.21. Statistical analysis
Data were analyzed using GraphPad Prism software version 6.0. Unpaired twotailed Student's t-test for pairwise comparison between the groups to determine
significant differences in viral loads (RNA levels and infectious titer) was performed.
Two-way ANOVA was used to determine significant differences between untreated and
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drug-treated samples for viral loads (RNA copies, infectious titer) for GQ binding ligand
studies. Data were represented as mean ± SEM.

2.22. Ethics statement
All procedures involving animals were conducted in accordance with the
guidelines established in the Guide for Care and Use of Laboratory Animals of the
National Institutes of Health, USA. The protocol was approved by the Institutional
Animal Care and Use Committee at the University of Nebraska-Lincoln. Animals were
housed in Life Sciences Annex building at the University. Mice were anesthetized with
isoflurane prior to inoculation or blood collection and all efforts were made to minimize
animal suffering.
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Primer

Sequence (5ʹ to 3ʹ)

Name

Application

GATCCGCTAGCGCCGCCACCATGGATGCAATGAAGA
A_F

GAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAG

Amplification

TCTTCGTTTCGATTAGATGTATTGGAGTCAGCAAC

of tPA-solE-F

AG
GATCCGCTAGCGCCACCATGGGGATCCTTCCCAGCC
CTGGGATGCCTGCGCTGCTCTCCCTCGTGAGCCTTCT
B_F

CTCCGTGCTGCTGATGGGTTGCGTAGCTGAAACCGG
TATTAGATGTATTGGAGTCAGC

Amplification
of µphosphatase
signal
sequencesolE-F

C_R

AGAGTCGCGGCCGCTTAGGATTTTC

D_F

GCAGCTCCCGGGCTGTGTCTTACAGCCTGTGCAC

495_F

GTCGTAACAACTCCGCCC

Amplification
of solE-F
Amplification
of zDIII-F
Primers used

1191_F

GGCCTTGACTTTTCAG

1856_F

GGAAATGCAGTCTTCC

2403_R

TCAGGTTCAGGGGGAG

to sequence
pIRES-solEF/zDIIIF

Table 2.1. Primers used for solE-F/zDIII-F construction. Restriction enzyme sites are
underlined. E protein/zDIII/Ferritin sequences are shown in bold letters. F- Forward
primer, R- Reverse primer. In A_F/B_F primers NheI site was incorporated. In C_R
primer NotI site was incorporated. In D_F SmaI/XmaI site was incorporated.
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CHAPTER III: CONSTRUCTION AND CHARACTERIZATION OF A
NANOPARTICLE-BASED VACCINE CANDIDATE AGAINST ZIKV

3.1. Abstract
ZIKV recently emerged in Brazil and caused a variety of diseases including
microcephaly in infants and GBS in adults. The virus spread expeditiously to many
countries and became a worldwide public health concern. Substantial strides have been
made in developing vaccine candidates against ZIKV infections. However, no FDAapproved and licensed vaccines are currently available for ZIKV. Herein, we describe
the development of a bacterial ferritin-based nanoparticle vaccine candidate for ZIKV
and highlight its potential as a safer and efficacious vaccine in comparison to existing
approaches. Since the domain III (DIII) of the envelope (E) protein of ZIKV induces
strong neutralizing antibody responses without causing antibody-dependent enhancement
(ADE) of infection, we chose to use DIII as a proof-of-principle of the approach. In this
approach, the DIII of ZIKV E protein was fused at the amino-terminus of the
Helicobacter pylori ferritin with a flexible linker (Ser-Gly-Gly). The fusion construct
(zDIII-F) also contained a secretion signal at its amino-terminus to allow secretion of the
protein (or nanoparticle) from transfected mammalian cells. Following expression and
purification, the nanoparticle vaccine candidate displaying the DIII on the particle surface
was found to induce higher levels of humoral responses in vaccinated animals compared
to the DIII antigen alone. A single dose of zDIII-F induced high levels of neutralizing
antibody responses in vaccinated A129 (IFNAR−/−) mice, and conferred protection
against lethal ZIKV challenge. Passive transfer of sera from mice vaccinated with
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zDIII-F protected A129 mice against subsequent lethal ZIKV challenge. The results
point to a promising and potentially more efficacious vaccine candidate based on the
ferritin nanoparticle platform.

3.2. Introduction
The recent re-emergence and spread of ZIKV in the Americas and its association
with microcephaly and other neurological symptoms in infants and Guillain-Barre
syndrome in adults posed a significant threat to human health (Coyne and Lazear, 2016;
Cugola et al., 2016; Pattnaik et al., 2018). While several drug and vaccine candidates are
in clinical testing phases, none have been approved for use in treating ZIKV infections.
Vaccines based on conventional live attenuated viruses have safety concerns given the
potential for reversal to virulence, especially in immunocompromised individuals (LopezSagaseta et al., 2016; Plotkin, 2014). Inactivated virus-based vaccines, on the other hand,
are comparatively less efficient in promoting protective immune responses. The
development of a vaccine platform involving self-assembling protein nanoparticles that
have the ability to display multiple copies of the antigen on the surface has emerged as an
alternative to conventional strategies. Such a platform can be instrumental in overcoming
the issues associated with conventional vaccine platforms and aid in the development of
safer and more efficacious vaccines (Lopez-Sagaseta et al., 2016; Plotkin, 2014).
Furthermore, the observations that our immune system responds more efficiently to
immunogens of the sizes in the nanometer range (Gause et al., 2017; Link et al., 2012)
suggest that the efficacy of nanoparticles displaying multiple copies of an antigen as
vaccines is likely to exceed that of a soluble monomeric antigen.
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The advantage of nanoparticle based vaccines lies in the fact that multiple copies
of the immunogen can be displayed on the surface of the nanoparticle as an ordered
antigenic array that results in multivalent B-cell receptor (BCRs) binding events (Fig.
3.1A). This is in contrast to monovalent binding events associated with conventional
vaccine approaches and leads to an immune response that is multitudes of magnitude
higher than traditional vaccines (Bachmann and Jennings, 2010; Lopez-Sagaseta et al.,
2016). Furthermore, the suitability of nanoparticle-based vaccines for large scale
production adds to the growing interest in this approach.
Several naturally occurring proteins can self-assemble to form stable and
structurally organized nanoparticles with optimum dimensions that make them suitable to
serve as vaccine delivery platforms (Lee and Wang, 2006; Lopez-Sagaseta et al., 2016).
One such example is ferritin, a protein found in all living organisms and functions in iron
storage and protects cells from damage caused by reactive oxygen species generated by
exposure to excess iron (Cho et al., 2009; Lopez-Sagaseta et al., 2016). The mammalian
and insect ferritins are multimeric proteins composed of 24 subunits of any combination
of heavy and light chains that are secreted by cells (Hamburger et al., 2005). However,
the bacterial ferritin nanoparticle is composed of 24 identical subunits that are
structurally organized to form an octahedral structure and is reported to be resistant to
thermal and chemical degradation (Fig. 3.1B) (Cho et al., 2009; He and Marles-Wright,
2015; Lopez-Sagaseta et al., 2016). The first report of using ferritin nanoparticles as a
vaccine platform demonstrated that influenza virus hemagglutinin (HA) could be
displayed on the surface of a ferritin nanoparticle in its native trimeric form. Inoculation
of these particles resulted in higher induction of neutralizing antibodies, thus providing
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evidence for more potent immune responses (Kanekiyo et al., 2013). This strategy has
been used successfully in the development of a universal influenza vaccine, which has
shown promising results with heterotypic protection (Yassine et al., 2015), as well as in
the development of vaccines against Epstein-Barr virus and HIV (Kanekiyo et al., 2015;
Zhou et al., 2014). Most recently, ferritin nanoparticle-based vaccine candidates have
been developed for SARS-CoV-2 using the full-length spike (S) protein or the receptor
binding domain of the S protein (Kalathiya et al., 2021; Kim et al., 2021).
In this study, we sought to generate plasmid constructs encoding either the full
length or the DIII of ZIKV E protein as immunogens in association with ferritin.
Transfection of the plasmid constructs into eukaryotic cells resulted in the production of
the recombinant proteins that were secreted by the cells. The fusion protein encoding the
ZIKV DIII (zDIII-F) was then purified to homogeneity by ion exchange and size
exclusion chromatography. Under transmission electron microscopy, the ZDIII-F protein
was seen to form typical nanoparticle like structures. The recombinant protein or the
nanoparticle (zDIII-F) was found to be stable for prolonged periods of time. In animal
studies, this vaccine candidate was seen to induce significantly higher levels of
neutralizing antibody response compared to soluble DIII antigen alone and conferred
protection against lethal challenge. Furthermore, sera obtained from the immunized mice
also protected naïve mice from lethal challenge with ZIKV. The results provide support
for the use of the ferritin nanoparticle vaccine candidate for ZIKV for further clinical
evaluation.

3.3. Results
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Fig. 3.1. Basic principle of nanoparticle-based enhancement of immune response.
(A) Monovalent recombinant antigens as in traditional vaccine platforms bind to fewer
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BCRs resulting in weaker immune response (left). In nanoparticle-based vaccine
platform, multiple immunogens can be structured on the surface leading to tighter and
prolonged binding with several BCRs (right). This enables the clustering of BCRs for
multiple and simultaneous engagement with the antigen epitopes. The B cells trap the
antigen-loaded nanoparticle to establish a durable, localized, and strong recognition that
translates into B-cell intracellular signaling, internalization, and processing of the antigen
for presentation via molecules of the MHC complex to the T follicular helper cells (Tfh)
within the germinal centers. Image adapted from López-Sagaseta et al, 2016. (B)
Organization of a ferritin nanoparticle showing each of the subunits and the structure of a
single subunit. Image adapted from Zhang and Orner et al, 2011.
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3.3.1. Construction and expression of full-length soluble E protein fused in-frame
with ferritin
The coding sequence of ferritin (aa residues 5-167) from Helicobacter pylori (H.
pylori) was synthesized using commercial gene synthesis service from GenScript (New
Jersey). The coding sequence of ferritin was then subcloned into the CMV-promoter
driven mammalian expression vector, pIRES-2-eGFP after removing the eGFP
sequences. Subsequently, the coding sequence of ZIKV E protein spanning residues 1 to
404 was PCR amplified from the full length infectious clone (Annamalai et al., 2017) of
ZIKV as the template. The amplified product thus lacked the carboxy-terminal
transmembrane and cytoplasmic domains. The E protein coding region was strategically
placed at the N terminus of ferritin for it to be exposed on the outside of the nanocage. It
has been reported that removal of the first 4 amino acids from the amino-terminus of
ferritin and immunogen fusion at that site results in the exposure of the immunogen to the
outside leading to better visibility of the antigen to BCRs (Kanekiyo et al., 2013).
To allow for secretion of the E-ferritin chimeric protein from the transfected cells,
we also inserted a consensus signal sequence, called secrecon signal (Guler-Gane et al.,
2016), at the amino-terminus of the chimeric protein that is known to drive efficient
secretion of proteins. Additionally, the linker, Ser-Gly-Gly (SGG) was also inserted
between the soluble E and ferritin coding regions as shown (Fig 3.2.A-B) to allow for
flexibility of the E protein to fold into its correct conformation and structure. Once the
construct was generated, the authenticity of the cloned sequences was confirmed by DNA
sequencing. The resulting chimeric protein, solE-F (Fig. 3.2.B) is expected to be about 68
kDa after removal of the signal sequences. To examine the expression and secretion of
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the solE-F protein, HEK293T cells were mock-transfected (no plasmid) or transfected
with two different concentrations of the plasmid (1 µg and 2.5 µg) encoding solE-F. The
cell culture supernatants collected on day four post-transfection were subjected to
Western blotting with an antibody to detect the solE-F protein. A 68 kDa protein was
specifically detected in the culture supernatants of cells transfected with the plasmid
encoding solE-F (Fig. 3.2.C, lanes 4 and 5) that was absent in mock-transfected cells
(lane 3). While the cells transfected with 1 µg plasmid DNA expressed lower amounts of
the protein (lane 4), transfection with 2.5 µg of the plasmid DNA led to higher level of
expression and secretion of the protein into the cell culture medium (lane 5).
Although the secrecon signal sequence in our construct resulted in good levels of
secretion of the solE-F protein into the supernatants of transfected cells, in order to obtain
more efficient secretion of the protein for large scale purification purposes, we examined
if other secretion signal sequences would allow for more efficient secretion. Several
signal sequences have been shown to drive efficient secretion of proteins (Dalton and
Barton, 2014). Therefore, we constructed similar plasmids (as shown in Fig. 3.2.A)
containing signal sequence from tissue plasminogen activator (tPA) (Kou et al., 2017) or
from the µ-phosphatase signal sequence present in the pHLvector (Aricescu et al., 2006).
Examination of the relative levels of secretion of solE-F from transfected cells directed
by these signal sequences revealed that although the other signal sequences directed
secretion of the protein (Fig. 3.2D, lanes 4-7), the secrecon signal sequence that we used
initially in our construct (Fig. 3.2.A) appeared to be most efficient in promoting secretion
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Fig. 3.2. Construction of the plasmid encoding solE-F fusion protein and expression
in transfected cells. (A) Schematic of the plasmid showing various coding regions and
regulatory elements for expression of the protein. CMV, cytomegalovirus promoter; K,
Kozak sequences; Sec, secretion signal sequences, solE, coding region of ZIKV E protein
from residues 1-404; and ferritin coding sequences from residues 5-167. The flexible

63

linker SGG is shown as a green rectangle between solE and ferritin sequences. Unique
restriction enzyme sites in the plasmid are shown at the top. (B) Amino acid sequence of
the solE-F fusion protein. The arrow shows the cleavage site following the secretion
signal sequences. (C) Expression of solE-F in 293T cells. Culture supernatants of cells
from mock-transfected (lane 3) or transfected with 1 µg (lane 4) or 2.5 µg (lane 5) of the
plasmid were analyzed by Western blotting for ZIKV E. solE-F (identified with an
asterisk) migrates as a ~68 kDa protein as compared to ~55 kDa ZIKV E protein (lane 2)
from virus-infected Vero cells. Molecular masses of marker proteins are shown on left.
(D) Secretion of solE-F from transfected cells directed by secretion signal sequences.
Supernatants of cells transfected with plasmids containing tPA signal sequence (lanes 4
and 5), µ-phosphatase signal sequence (lanes 6 and 7) and secrecon signal sequence
(lanes 8 and 9) were analyzed by Western blotting for solE-F secretion. Lane 2: ZIKV E.
Asterisk identifies the secreted solE-F protein.
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of solE-F protein (lanes 8 and 9). Therefore, the secrecon signal sequence was used in our
constructs.

3.3.2. Construction and expression of DIII domain of E protein fused in-frame with
ferritin
While conducting our studies, it became clear that immunization with full length
ZIKV E protein may contribute to antibody dependent enhancement (ADE) of infection
leading to more severe disease (Shukla et al., 2020a; Shukla et al., 2020b). To overcome
this and avoid ADE, parts of the ZIKV E protein can be used as an antigen. ZIKV E
protein consists of three domains. It has been reported that of the three domains, DIII
elicits a strong neutralizing antibody response in mice without inducing ADE (CabralMiranda et al., 2019). Therefore, we generated an expression plasmid that replaced the
solE coding sequences with the coding sequence of ZIKV E protein DIII (Fig. 3.3.A),
spanning amino acid residues 303 to 404. Following sequence confirmation of the DIII
region within the plasmid, we examined expression and secretion of the chimeric
protein, zDIII-F. HEK293T cells were transfected with the plasmid and culture
supernatant and cell lysates were harvested on day four post-transfection and subjected to
Western blotting. A protein band of approximately 27 kDa was detected in the
supernatant (Fig. 3.3.B, lane 3) by using an antibody directed against DIII of ZIKV E
protein. This protein was also detected in the transfected cell lysates (lane 2).
Interestingly, a slower migrating band of ~30 kDa was also observed in the cell pellet
(lane 2), which is likely the signal sequence-uncleaved version of the same protein.
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3.3.3. Large scale expression and purification of zDIII-F

Large scale expression using a suitable expression system and subsequent
purification of a recombinant protein is critical for the development and testing of
vaccine candidates. Expression of recombinant proteins in mammalian cell culture
systems is widely accepted for their ability to incorporate post translational modifications
such as addition of glycan moieties that are key to the proper folding and functioning of
proteins.
Although, widely accepted, this system is associated with a strict bottleneck while
purifying the recombinant protein due to the presence of serum-borne adventitious agents
that pose a risk of contamination. To overcome this bottleneck, the use of serum-free cell
culture medium has provided researchers with a system that allows for increased
production of the recombinant protein while getting rid of the issues associated with
using serum. Therefore, we used the 293FreeStyleSystem from ThermoFisher that
involves the use of 293FS suspension cell culture in a serum free medium to scale up the
production of zDIII-F and subsequent purification and experimentation. In initial pilot
experiments, we transfected 1 µg of the plasmid construct encoding zDIII-F per one
million 293FS cells in suspension using 293Cellfectin or polyethylenimine (PEI)
transfection reagents. Small aliquots of cell suspension were collected at days 2, 3, 4, and
5 post-transfection (dpt) and the presence of ZDIII-F protein in the supernatants was
examined by Western blotting. From the pilot experiments, we inferred that maximal
secretion of the protein occurred at 4 dpt and approximately 0.6-0.8 µg of the protein

66

Figure 3.3. Construction and expression of zDIII-F. (A) Schematic of the plasmid
encoding zDIII-F showing coding regions and regulatory elements for expression of the
protein similar to the plasmid described in Fig. 3.2. ZIKV domain III (DIII) sequences
span residues 303-404. (B) Expression of zDIII-F in 293T cells. Cells were transfected
with the above plasmid and 96 after transfection, cell lysates (lane 2) and supernatants
(lane 3) were analyzed by Western blotting for zDIII-F using an antibody against DIII.
Molecular masses of marker proteins are shown on left. The secreted zDIII-F protein of ~
27 kDa is identified by an asterisk on right.
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was present in one ml of the culture supernatant as judged by oriole staining of the
protein band. Therefore, we used these transfection conditions for large scale expression
and purification of ZDIII-F,.
For large scale expression and purification of ZDIII-F, a 500 ml culture of 293FS
cells at a density of 1 million cells per ml was transfected with 500 µg of plasmid DNA
encoding zDIII-F. Following incubation for 4 days, the clarified cell culture supernatant
was subjected to ion exchange chromatography to isolate zDIIIF. Since the zDIII-F
chimeric protein carries a calculated net charge of -13.84 at the physiologically relevant
pH of 7.4, we used an anion exchange column with a quaternary capto matrix to purify
zDIII-F from the culture medium. Using a combination of Tris buffers (pH 7.4)
containing 50 mM and 1000 mM NaCl, majority of presumed zDIII-F protein was eluted
in a relatively pure form (as judged by Coomassie staining) in pooled fractions
corresponding to NaCl concentration of 107-158 mM (Fig. 3.4.A, lane 2). Although
higher concentration of NaCl eluted the protein from the column, the amount of other
contaminating proteins was either significant or there was less zDIII-F (lanes 3-6).
Western blot analysis of the pooled fractions showed that the major band in the 107-158
mM NaCl pooled fraction was indeed zDIII-F protein (Fig. 3.4.B, lane 2). Based on
Coomassie staining, we estimated that the purity of the zDIII-F protein was
approximately 80-85%. To further purify the protein, we pooled the fractions
corresponding to 107-158 mM NaCl concentration and applied to a size exclusion
chromatography column. We confirmed the purity of the eluted protein to be
approximately 90-95% by SDS-PAGE analysis followed by Coomassie staining of the
gel (Fig. 3.5.C) and its identity by Western blot analysis using an antibody against DIII of
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Fig. 3.4. Anion exchange chromatograpy for purification of zDIII-F. SDS-PAGE and
Coomassie staining (A) and Western blot analysis (B) of various pooled fractions from
anion exchange column chromatography. Eluted zDIII-F protein detected in pooled
fractions from concentrations of NaCl ranging from 107-158 mM (lane 2), 159-214 mM
(lane 3), 215-271 mM (lane 4), 272-379 mM (lane 5) and 380-422 mM (lane 6) are
shown. Approximately 1 µg of total protein in panel A and 100 ng of total protein in
panel B were analyzed. Molecular masses of marker proteins are shown on left side of
each panel.
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ZIKV E (Fig 3.5.C).

3.3.4. zDIII-F forms stable nanoparticles as visualized by transmission electron
microscopy (TEM)
Since ferritin spontaneously self-assembles into nanoparticles, resembling a cage
like structure with 24 units (Lopez-Sagaseta et al., 2016), my expectation was that we
will observe the purified zDIII-F chimeric protein as a nanoparticle with the zDIII region
protruding out from the surface of the nanoparticle. Indeed, structural prediction of zDIIIF chimeric protein based on the known structures of ferritin (PDB ID: 3BVE) and the
ZIKV E DIII protein (PDB ID: 5JHM) revealed that the DIII region of the E protein folds
independently and protrudes from the amino-terminal end of ferritin molecule (Fig.
3.6.A). Two dimensional TEM images of purified zDIII-F show the formation of
spherical structures about 12-15 nm in diameter with protruding structures indicating that
the recombinant protein is able to form a nanocage-like structure with the zDIII likely
protruding from its surface (Fig. 3.6.B). We attempted to perform cryo-EM structural
analysis of a highly purified preparation of zDIII-F. However, our collaborator Dr. Terje
Dokland, University of Alabama at Birmingham was unable to detect any density on the
surface of ferritin particles and suggested that the presence of the highly flexible linker
(SGG) between ferritin and DIII might have contributed to the inability to detect density
of DIII. Therefore, future chimeric protein constructs may be designed without the use of
the flexible linker sequences.Ferritin is a stable protein and is known to be resistant to
degradation even when exposed to high temperatures. Indeed, a study reports that a
vaccine candidate using the ferritin platform is thermally stable and retains its potency
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Fig. 3.5. Examination of purity of zDIII-F following size exclusion chromatograpy.
SDS-PAGE followed by Coomassie staining (A) and Western blot analysis (B) of zDIII-F
after purification using size exclusion column chromatography. Approximately1 µg of
total protein in panel A and 100 ng of total protein in panel B were analyzed. Asterisk on
right identifies the zDIII-F protein. Molecular masses of marker proteins are shown on
left.
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even after exposure to high temperatures for prolonged periods of time (Lopez-Sagaseta
et al., 2016). Consistent with the known stability of proteins fused to ferritin, we
observed that the zDIII-F chimeric protein was stable as judged by SDS-PAGE analysis
of zDIII-F samples taken every 15 days post storage at 4⁰C, showing minimal or no
degradation of the protein (Fig. 3.6.C). Additionally, TEM images of particles in samples
taken at every 30 days show intact nanoparticles that appear similar to those observed on
the day of isolation (Fig. 3.6.D). These data demonstrate that the zDIII-F nanoparticles
are stable at 4⁰C for up to 90 days.

3.3.5. Mice immunized with zDIII-F are protected from lethal ZIKV challenge
To evaluate the efficacy of the zDIII-F nanoparticle vaccine compared to soluble
DIII domain of ZIKV as a vaccine, we acquired the soluble DIII antigen from ProSpec
(Cat# ZKV-008). Three-week-old Ifnar1−/− A129 mice were divided into three groups:
PBS group (n=6), DIII group (n=7), and zDIII-F group (n=7). Mice were injected with
either PBS (PBS group), 4 g of soluble ZIKV DIII protein per animal (DIII group), or
10 g of the zDIII-F nanoparticle vaccine (equivalent to 4 g of zDIII antigen) per
animal (zDIII-F group) formulated with Addavax adjuvant. We monitored the mice for
28 days and then challenged them subcutaneously with 10,000 pfu of ZIKV
(infectiousclone derived rMR virus) per mouse. The mice were monitored and scored for
clinical signs, weight loss, and survival for 10 days at which time the surviving mice
were euthanized (Fig 3.7.A).
At 2-3 dpi, the mice in the PBS group and infected with rMR, began showing
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Fig. 3.6. Characterization of zDIII-F fusion protein and nanoparticles. (A) Predicted
structure showing folding of zDIII-F fusion protein as two separate domains linked by the
SGG linker. The ribbon structure was generated by Dr. Santosh Behera (NIPER, India)
using PyMOL software and PDB IDs: 3BVE (H pylori ferritin) and 5JHM (ZIKV E
DIII). (B) TEM image of purified zDIII-F nanoparticles. (C) Stability of zDIII-F fusion
o

protein following incubation at 4 C with time. Two hundred ng aliquots of the protein
o

were taken from a purified preparation at every 15 day intervals and stored at -80 C
before analysis. Following SDS-PAGE, protein bands were visualized by oriole staining.
o

Lanes 2-8 contain proteins from day 0, 15, 30, 45, 60, 75, and 90 post-incubation at 4 C,
o

respectively. (D) TEM images of particles after 0, 30, 60, and 90 days of storage at 4 C.
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Fig. 3.7. zDIII-F vaccinated animals are protected from lethal ZIKV challenge. (A)
Strategy for vaccination and lethal challenge using four-week-old A129 mice. Mice were
injected with PBS (n=6), 4 µg of DIII (n=7) or 10 g of zDIII-F (n=7) subcutaneously
4

(s.c.) on day 0 and challenged with rMR (10 PFU/mouse) on day 28. Blood samples
were collected on days 2, 4, and 6 post challenge. (B) Clinical symptoms developed in
individual mouse (identified as A to F/G in various groups) following lethal ZIKV
challenge.
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signs of disease such as shivering and ruffled fur which by day 3-4 progressed to
conjunctivitis, lethargy, and hunched posture (Fig 3.7.B). Additionally, some mice
presented with both fore limb and hind limb paralysis beginning at 4 dpi which extended
till day 6. All the mice in this group developed severe disease signs and succumbed to
virus infection by 7 dpi with one mice each dying at 5 dpi and 6 dpi (Fig 3.7.B, PBS
group). Mice in soluble DIII-vaccinated group appeared healthy for 3 dpi but 3 mice
developed clinical symptoms exhibiting ruffled fur, conjunctivitis, followed by limb
paralysis by day 6 and ultimately succumbing to infection by day 8. All other mice in this
group were healthy until day 10, at which time they were euthanized. In contrast, 5 out of
7 mice in the zDIII-F group showed no symptoms of disease at even at 10 dpi. Two mice
presented ruffled fur and shivering on 3 dpi which continued till 4 dpi but one mouse
recovered completely while the other mice exhibited more severe symptom and
succumbed on day 8 (Fig 3.7.B). At the end of the experiment on day 10 when they were
euthanized, all mice (except one that died on day 8) in this group appeared healthy.
Weight loss was observed in all mice administered with PBS and infected with rMR by 2
dpi (Fig 3.8.A) and this trend continued until they succumbed to virus infection. One
mouse each succumbed to infection on day 5 and 6 (Fig 3.8.B) and by 7 dpi, all mice in
this group had perished (Fig 3.8.B). On the other hand, mice vaccinated with soluble DIII
or zDIII-F and infected with rMR virus did not exhibit any weight loss. In fact, most mice
in these groups began to gain weight after about 3 dpi and the trend continued up to 10
dpi (Fig. 3.8.A). Three mice from soluble DIII vaccinated group died on day 8, whereas 6
out of 7 mice in zDIII-F vaccinated group survived the virus infection until 10 dpi when
all the mice were euthanized (Fig 3.8.B).
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Fig. 3.8. zDIII-F vaccinated animals are protected from lethal ZIKV challenge. (A)
Weight change and (B) Percent (%) survival of mice in PBS or DIII or zDIII-F vaccinated
groups. (C) Viral genome copies in serum at days 2, 4, and 6 post-challenge as measured
by qRT-PCR. Data presented as ± SEM. Two-way ANOVA was used to determine
significance. Ns, non-significant; **, p  0.01, ****, p  0.0001.
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Viral genome copy numbers in the serum of the infected mice were significantly
reduced genome copies in the soluble DIII-vaccinated and zDIII-F-vaccinated groups
at 2 dpi in comparison to mice in the PBS group (Fig 3.8.C). At days 4 and 6 postinfection, significantly lower number viral genome copy numbers were detected in the
majority of the animals in the two vaccinated groups. On the other hand, high levels of
viral genomes were detected in all animals administered with PBS. These results indicate
that the nanoparticle based zDIII-F vaccine protects Ifnar1−/−A129 mice from lethal
challenge and that zDIII-F appears to be a more efficacious vaccine candidate in
protecting the animals and reducing viremia than the soluble DIII antigen.

3.3.6. Vaccination with zDIII-F elicits high levels of neutralizing antibody
To determine if zDIII-F nanoparticle induces neutralizing antibody responses
against ZIKV infection, we examined the presence of neutralizing antibodies in the serum
samples of zDIII-F vaccinated A129 mice collected at 28 days post-vaccination. Results
show significantly higher neutralizing antibody titers (PRNT50) in sera from zDIII-F
nanoparticle vaccinated animals in comparison to sera from animals from PBS
administered group (Fig. 3.9.A). Interestingly, the antibody titers elicited by zDIII-F was
significantly higher than those elicited by soluble DIII antigen (Fig. 3.9.A). Overall, these
results indicate that vaccination with zDIII-F elicits a strong neutralizing antibody
response that protects mice from lethal ZIKV (rMR) challenge whereas vaccination with
soluble DIII confers protection to a lesser degree. To determine if the antibodies induced
by zDIII-F vaccination can neutralize different ZIKV strains from recent outbreaks, we
performed a PRNT50 assay with the serum from zDIII-F vaccinated mice. We used the
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Fig. 3.9. Neutralizing antibody titers in the sera of zDIII-F vaccinated animals. (A)
The ZIKV neutralizing antibody titers in serum [expressed as reciprocal of 50% plaque
reduction neutralization test (PRNT50) values] from naïve or zDIII-F vaccinated mice at
28 dpi. (B) PRNT50 titer of serum samples from individual animals vaccinated with
zDIII-F against PRVABC59 and MEX1-7 strains of ZIKV. (A) Data in panel A are
presented as ± SEM. Two-way ANOVA was used to determine significance. **, p≤0.01;
***, p ≤ 0.001; ****, p ≤ 0.0001.
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PRVABC59 and MEX1–7 strains of ZIKV that are currently in our laboratory. The
results show potent inhibition of all ZIKV strains with similar PRNT50 values, suggesting
that the zDIII-F vaccine candidate may confer protection against other ZIKV strains (Fig.
3.9.B).

3.3.7. Passive transfer of antibodies from animals vaccinated with zDIII-F protects
mice from lethal challenge
To explore the possibility that serum antibodies from zDIII-F vaccinated animals
could protect mice form lethal ZIKV infection, we conducted a passive antibody transfer
experiment in A129 mice. Mice were divided into two groups: one group (n=10) received
sera obtained from mice that were administered with PBS while the other group (n=10)
received sera from mice vaccinated with zDIII-F. The sera were collected at 28 days
post-vaccination (as shown in Fig. 3.7.A) and the pooled sera were administered to mice
by the intravenous route using the tail vein. The mice were challenged with 10,000 pfu
ZIKV at 4 hours post sera administration and were monitored for disease progression for
10 days (Fig. 3.10.A). The mice that received sera from PBS-administered animals
developed disease with half of them showing ruffled fur and shivering at 2 dpi. By 3 dpi,
some mice (n=3) developed conjunctivitis, lethargy, and hunched posture (Fig. 3.10.B).
In contrast, 8 out of 10 mice that received sera from zDIII-F-vaccinated animals appeared
healthy until termination of the experiment, while one animal progressively exhibited
symptoms and succumbed to infection on day 9 and the other exhibited symptoms early
but recovered (Fig. 3.10.B). At 4 dpi, we sacrificed 5 mice from each group. The
remaining 5 mice that received sera from PBS-administered animals developed severe
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Fig. 3.10. Passive transfer of sera from zDIII-F vaccinated animals protects naïve
animals from lethal ZIKV challenge. (A) Strategy for passive transfer of immune sera
and lethal ZIKV challenge in four-week-old A129 mice. Mice were injected with 200 µl
of PBS (n=10) or pooled sera from zDIII-F vaccinated animals (n=10) intravenously at 0
4

hr and challenged with rMR (10 PFU/mouse) at 4 hr. Blood samples were collected on
days 2, 4, and 6 post lethal challenge. (B) Clinical symptoms developed in individual
mouse (identified as A to J in each group) following lethal ZIKV challenge are shown.
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disease and by 6-7 dpi, all five mice succumbed (Fig. 3.11.B) while 4 out of the
remaining 5 mice that received sera from zDIII-F-vaccinated mice did not exhibit any
clinical signs of disease and survived (Fig. 3.10.B). However, one mouse from this group
died on day 9. The mice that received sera from PBS-administered animals also began to
lose weight and by 4 dpi, weight loss was significant while the mice in the other group
continued to gain weight (Fig. 3.11.A). These results suggest that passive transfer of sera
from zDIII-F-vaccinated animals protected the mice against rMR virus lethal challenge.
Determination of viral genome copies in serum samples collected from mice in
both groups showed that the mice that received the sera from zDIII-F vaccinated animals
had significantly lower viral genome copies in comparison to the mice that received the
sera from PBS-administered mice (Fig. 3.11.C). Additionally, viral genome copies in the
brain, spleen, and the liver were also greatly reduced in mice that received the sera from
zDIII-F-vaccinated animals (Fig. 3.11.D). These results demonstrate that passive transfer
of sera obtained from mice vaccinated with zDIII-F confers solid protection against lethal
ZIKV challenge.

3.4. Discussion
The emergence of ZIKV in the western hemisphere and its association with
neurological disease in infants as well as adults poses a serious concern to public health.
Licensed vaccines or antiviral drugs to treat ZIKV infections are not available thereby
necessitating the development of countermeasures against this viral epidemic. Although
several different vaccine strategies have been developed and are being tested (Pattnaik et
al., 2020), none have been approved for clinical use. Therefore, an efficacious vaccine is
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Fig. 3.11. Passive transfer of sera from zDIII-F vaccinated animals protects naïve
animals from lethal ZIKV challenge. Percent weight change (A) and survival (B) of
mice injected with immune sear from naïve or zDIII-F vaccinated animals. (C) Viral
genome copies in serum at days 2, 4, and 6 post challenge. (D) Viral genome copies per
gram of tissues as measured by qRT-PCR. Data presented as ± SEM. Two-way ANOVA
was used to determine significance in panels C and D. ***, p ≤ 0.001; ****, p ≤ 0.0001.
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still much sought after. Since ZIKV infections have occurred in DENV endemic areas
and the observations that cross-reactive antibodies can cause ADE (Kawiecki and
Christofferson, 2016; Stettler et al., 2016; Zimmerman et al., 2018), attention must also
be paid in the development of efficacious ZIKV vaccines that do not induce ADE of
DENV or ZIKV infections. Furthermore, due to detection of ZIKV infections in many
countries, particularly in resource-limited developing countries, rapid production of
vaccines in a cost-effective manner would be highly desirable.
Although our initial plan was to use the ectodomain of E protein as the target for
development of a vaccine candidate based on the studies showing that neutralizing
antibodies that are protective against ZIKV infections are mostly directed against the E
protein, it has become clear that such antibodies have the potential to induce ADE.
Therefore, we focused on using the DIII domain of the ZIKV E protein, which has been
shown to not induce ADE (Cabral-Miranda et al., 2019; In et al., 2020; Shukla et al.,
2020c; Yang et al., 2017b) .
Nanoparticles provide an improved vaccine platform for the delivery of antigens
and have been in clinical development against several infectious diseases (LopezSagaseta et al., 2016). Ferritin is a stable protein that has the ability to self-assemble into
nanoparticles and this property has been exploited in the development of vaccine
candidates against several pathogenic viruses. In this study, we have developed the
bacterial ferritin-based vaccine candidate that displays the ZIKV E DIII as the antigen
that has been shown to self-assemble into nanocage like structure with the antigen
displayed on its surface. The zDIII-F protein and the nanoparticles were found to be
resistant to degradation and maintained structural integrity when left at 4⁰C for up to 3
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months, demonstrating a desirable property of thermostability of a vaccine candidate.
While designing our nanoparticle construct, we rationalized that by adding a
flexible linker between DIII and ferritin sequences would allow the DIII to be displayed
on the surface of the nanoparticle in its native structure for it to be recognized efficiently
by the B cells. However, attempts to determine its structure by cryo-EM was
compromised due to the presence of the flexible linker sequences. Insertion of a less
flexible linker sequence or direct fusion of DIII with ferritin may allow determination of
the DIII structure that would be visible by the immune cells. It would be interesting to see
if a construct such as the one without a flexible linker would induce stronger
immunological response as compared to the one I have described here. The use of the
consensus secrecon signal sequence in the plasmid construct for this vaccine candidate
greatly enhances the ability of the synthesized protein to be secreted into the culture
medium from which it can be purified in a simple and easily up-scalable purification
process.
Previous studies have shown that HA-ferritin nanoparticles induce neutralizing
antibody response against a number of pathogens including influenza virus (Kanekiyo et
al., 2013), HIV-1 (Sliepen et al., 2015), and Epstein Barr virus (Kanekiyo et al., 2015).
Most recently, ferritin nanoparticles have also been used for multivalent display of
SARS-CoV-2 spike protein RBD domain (Kalathiya et al., 2021) resulting in induction of
potent neutralizing antibodies that could protect ferrets from the virus challenge (Kim et
al., 2021). In line with these observations, we have demonstrated that immunization of
mice with ferritin-based nanoparticles (zDIII-F) displaying ZIKV E DIII elicits a strong
antigen specific neutralizing antibody response which correlates with protection of
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animals against lethal ZIKV challenge. The neutralizing antibody response was
approximately ten-fold higher than those obtained with the conventional soluble DIII
antigen.
The results reported in this study demonstrate that immunization of mice with
zDIII-F markedly reduces viral load, alleviates disease symptoms, and protects mice
against lethal ZIKV infection. Additionally, passive transfer of sera from immunized
animals confers protection in mice by decreasing viral load in serum as well as in tissues.
Furthermore, the neutralizing potency of zDIII-F induced antibodies against two other
recent ZIKV isolates (PRVABC59 and MEX1-7, both belonging to Asian strain) from
recent outbreaks was found to be very similar to the homologous strain (rMR, belonging
to African strain), whose DIII sequence was used for vaccine construction, suggesting
that the zDIII-F vaccine candidate may protect both African and Asian strains of the
virus.
In the vaccination regimen used here, we found that a single dose of zDIII-F
nanoparticles induced significantly higher neutralizing antibody response as compared to
the soluble DIII. Although I only used one dose (10 µg) of the nanoparticle vaccine, the
possibility exists that increasing the antigen dose and/or employing a prime-boost
strategy may further enhance the levels of neutralizing antibody responses. In a previous
study, a ZIKV vaccine candidate displaying the E-DIII domain on an immunologically
optimized cucumber mosaic virus-derived VLP was shown to induce high levels of
specific IgG after a single injection that could neutralize ZIKV in vitro (Cabral-Miranda
et al., 2019). It should be noted that most DIII-based vaccine candidates in the form of
soluble antigens, nanoparticles, in tandem repeats, or having been displayed on the
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surface of VLPs were shown to induce neutralizing antibody responses to varying
degrees that were protective against ZIKV (Chen et al., 2020; Cibulski et al., 2021; In et
al., 2020; Shukla et al., 2020c; Yang et al., 2017a; Yang et al., 2017b). However, an
exception to this was reported in a study (Lopez-Camacho et al., 2020) showing that DIII
conferred limited protection against ZIKV and suggested that the DIII may not be an
appropriate vaccine candidate for induction of immune responses against ZIKV. The
reason(s) for this discrepancy is not known at this time and clearly further research is
necessary. Our results showing that zDIII-F induces high levels of protective neutralizing
antibody responses are consistent with the majority of the previous studies.
In attempts to understand the mechanism(s) of protection conferred by zDIII-F
vaccine, we have found significantly higher levels of total IgG and IgG2a, which may
indicate that Th1 type cellular response likely contributes to the generation of specific
antibody classes for protection (preliminary findings). Additionally, IFN-γ+ CD4 and
CD8 cells were also significantly increased, indicating a strong cellular immune response
as well. Although these results are preliminary and not included here, our overall data
suggest that both humoral and cellular responses are likely contributing factors for
protection induced by the zDIII-F vaccine candidate. We realize the limitations of the
data presented here such as the use of a single dose of the zDIII-F vaccine candidate,
single immunization, and examining the efficacy in immunocompromised mice.
Therefore, we have to be cautious in extrapolating our data from the mice model to ZIKV
infections in humans. Nevertheless, collectively, this study provides a proof-of-principle
for the feasibility of developing an efficacious ZIKV vaccine that uses a multivalent
delivery platform for enhanced immunological response against the virus.
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CHAPTER IV: IDENTIFICATION AND CHARACTERIZATION OF A NONNUCLEOSIDE INHIBITOR OF ZIKV RNA POLYMERASE

Part of the studies described in this chapter was published in Antiviral Research, 2018.
Pattnaik, A., Palermo, N., Sahoo, B.R., Yuan, Z., Hu, D., Annamalai, A.S. Vu, H.L.,
Correas, I., Prathipati, P.K., Destache, C.J., Li, Q., Osorio, F.A. Pattnaik, A.K. and
Xiang, S.-h. (2018). Discovery of a non-nucleoside RNA polymerase inhibitor for
blocking ZIKV replication through in silico screening. Antiviral Research, 151: 78-86.
doi.org/10.1016/j.antiviral.2017.12.016
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4.1. Abstract
ZIKV, an emerging arbovirus, has become a major human health concern globally
due to its association with congenital abnormalities and neurological diseases. Licensed
vaccines or antivirals against ZIKV are currently unavailable. Studies reported here
describe our attempt to identify and characterize a small molecule inhibitor of ZIKV
replication. At the time these studies were undertaken, the structure of the ZIKV RNAdependent RNA polymerase (RdRp) was not known. Therefore, we first predicted the
structure of the viral RdRp through homology modeling using the known structure of the
RdRp of dengue virus (DENV), which is closely related to ZIKV. Subsequently, by
employing a structure-based approach targeting the ZIKV RdRp, we conducted in silico
screening of a library of 100,000 small molecules and tested the top ten lead compounds
for their ability to inhibit the virus replication in cell-based in vitro assays. One
compound, 3-chloro-N-[((4-[4-(2-thienylcarbonyl)-1 piperazinyl]phenyl)amino)
carbonothioyl]-1-benzothiophene-2-carboxamide (TPB), potently inhibited ZIKV
replication at submicromolar concentrations. Molecular docking analysis suggested that
TPB binds to the catalytic active site of the RdRp and therefore likely blocks the viral
RNA synthesis by an allosteric effect. The inhibitory concentration 50 (IC50) and the
cytotoxicity concentration 50 (CC50) of TPB in Vero cells were found to be 94 nM and
19.4 μM, respectively, yielding a high selective index of 206. In in vivo studies using
immunocompetent mice, TPB reduced ZIKV viremia significantly, indicating TPB as a
potential drug candidate for ZIKV infections.
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4.2. Introduction
ZIKV has a single positive-strand RNA genome of ∼11 kilobases and replicates
using the viral RNA-dependent RNA polymerase (RdRp). Since the RdRp is a key
enzyme for ZIKV replication, it is an attractive target for antiviral drug development
(Duan et al., 2017; Ramharack and Soliman, 2018; Wang et al., 2017). During
replication, the viral positive-sense RNA genome is translated into a single polypeptide
that is subsequently cleaved by viral and host proteinases to generate three structural
proteins and seven non-structural (NS) proteins (Baronti et al., 2014; Perera and Kuhn,
2008). The NS5 is the most conserved among the NS proteins and contains two domains
(Fig. 4.1): the methyltransferase (MTase) domain at the N-terminus (residues 1–264) and
the RdRp domain at the C-terminus (residues 275–903). The MTase is required for
mRNA capping and stabilization to facilitate translation process, to escape detection of
the viral mRNA by the host innate immune sensors as well as for cap-independent
methylation with yet unknown functions (Coutard et al., 2017), whereas the RdRp
domain is required for RNA synthesis. The structure of ZIKV RdRp, like other RdRps of
flaviviruses, adopts a typical right-hand shape architecture which includes three
subdomains: fingers, thumb and palm (Duan et al., 2017; Godoy et al., 2017; Upadhyay
et al., 2017; Zhao et al., 2017). A large cavity is formed at the junction of the three
subdomains. The palm subdomain contains several conserved motifs (A, B, C, D, and E),
one of which (motif C), contains the catalytic site residues, GDD (residues 664-666),
while the thumb subdomain contains the priming loop (Fig. 4.1). The cavity contains the
catalytic site for RNA polymerization, RNA entry and exit channels, and NTP entry
channel as well as the large priming loop which plays an important role in regulating
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Fig 4.1. The NS5 protein of ZIKV showing the amino-terminal methyltransferase
and carboxy-terminal RNA-dependent RNA polymerase (RdRp) domains. Various
subdomains in RdRp such as fingers, palm, and thumb subdomains as well as some key
structural motifs in palm and thumb subdomains with residue numbers spanning these
motifs have been identified. Motif C contains the catalytic active site residues, GDD.
Adapted from Zhao, B. et al. (2017), Nature Communications, 8:14762.
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RNA synthesis and elongation. This large cavity in the RdRp of other viruses has become
a major target for antiviral drug development (Choi and Rossmann, 2009; Duan et al.,
2017; Shi and Gao, 2017).
In this chapter, we sought to generate a predicted three-dimensional model of
ZIKV RdRp for virtual drug screening. At the time I initiated this project, the threedimensional structure of the ZIKV RdRp was not known. Since dengue virus (DENV) is
closely related to ZIKV, we used the known DENV RdRp structure to perform homology
modeling for prediction of the structure of the ZIKV RdRp. Following that, the large
cavity containing the active site and the priming loop in ZIKV RdRp was chosen as a
target for the structure-based drug screening. In silico screening approach was employed
to search for compounds that target this large cavity and a library containing about
100,000 small molecule compounds was screened. Subsequently, we identified 10 small
molecule compounds with top scores for their ability to bind to this large cavity and then
tested their activity to inhibit virus replication in in vitro assays. Amongst these top 10
small compounds, one compound, 3-chloro-N-[((4-[4-(2-thienylcarbonyl)-1piperazinyl]phenyl)amino) carbonothioyl]-1-benzothiophene-2-carboxamide (TPB), was
found to inhibit ZIKV replication in cell based assays with high potency at
submicromolar concentration and reduced viremia in immunocompetent mice. Hence, we
propose its potential as a drug candidate for further development against ZIKV.

4.3. Results
4.3.1. Generation of 3-D structure of RdRp domain of NS5 protein
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In 2016, when this project was initiated, the crystal structure of ZIKV NS5
protein (the viral RdRp) was not available. To generate a 3-D model of RdRp, we first
aligned the amino acid sequences of ZIKV RdRP with the amino acid sequences of the
RdRp of the closely related DENV strain 3 (DENV-3). The RdRp amino acid sequence
of the historical strain MR766, 1947 Uganda isolate (accession number: KU720415) and
sequence of DENV-3 (accession number: AY662691) were selected from the NCBI
database. The sequence alignment was done by using Clustal Omega (EMBL-EBI) and I
found that RdRp of ZIKV sequence was highly homologous with RdRp of DENV-3 (Fig.
4.2), with 68% identity and 75% similarity. Since the high resolution (1.8 Å)
crystallographic structure of RdRp of DENV-3 was available (Yap et al., 2007), we used
this structure as a template to generate a predicted structure of ZIKV RdRp.
Like RdRp structures in other flaviviruses, the ZIKV RdRp structure model
showed a very similar right-handed architecture with fingers, palm, and thumb
subdomains (Fig. 4.3). The crystallographic structure of RdRp domain of ZIKV NS5
protein of the BeH819015 strain (Brazilian isolate) at 1.8 Å resolution (Duan et al., 2017)
was described after we predicted the structure through homology modeling. We
compared both the RdRp structures of ZIKV to determine the accuracy of our predicted
structure and was found to be superimposable with the reported crystal structure of ZIKV
RdRp (Fig. 4.3) with C-alpha atom root mean square deviation (RMSD) of 2.519. The
target site appeared to fit well and the relative larger RMSD value should be mainly from
the flexible loops and the outer layers of the three domains. This comparison result was
very satisfactory and confirmed that our predicted structure was in line with the actual
crystallographic structure (Duan et al., 2017).
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Fig. 4.2. Pairwise amino acid sequence alignment of ZIKV and DENV3 RdRp
domains. Sequence alignment was performed by Clustal Omega software. Amino acid
sequence of RdRp domain (residues 275-903) of ZIKV (accession #: KU720415) was
aligned with the corresponding sequences of DENV-3 RdRp domain (accession #:
AY662691). The catalytic motif (GDD) of the viral RdRp is boxed with a red rectangle,
conserved residue D535 is boxed with green rectangle, and the catalytic cavity used for
screening is boxes with a black rectangle.
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Fig. 4.3. Superimposition and alignment of 3-D structures of ZIKV RdRp domain.
The predicted RdRp structure (depicted in cyan) is generated based on the DENV-3 RdRp
structure. The actual crystal structure of ZIKV RdRp (PDB ID: 5WZ3), shown in yellow,
is superimposed on the predicted structure. The thumb, fingers, palm subdomains and
priming loop are shown. The drug target site is marked by pink box. The superimposed
ribbon structure was generated using PyMOL software.
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4.3.2. Virtual screening of a compound library against RdRp loops
In silico screening of a library of 100,000 small molecule compounds against the
catalytic active site on the ZIKV RdRp molecule was conducted. The active site is in the
palm sub-domain which is critical for de novo RNA synthesis performed by ZIKV RdRp
(Duan et al., 2019). Based on the in silico screening data, the top 10 compounds with
highest docking scores are shown in Table 4.1. The docking score represents how well
the compound fits into the cavity and binds to the residues surrounding the cavity. A
compound with a lower negative score would suggest its higher binding affinity to the
residues surrounding the cavity. The molecular weights of these ten compounds are also
similar, ~ 500 Da, which are in the appropriate range of druggable compounds. To test
their ability to inhibit virus replication in in vitro assays, we
purchased these top 10 compounds with the lowest docking scores from Hit2Lead
Company (ChemBridge Corporation). Following manufacturer’s recommendations, the
compounds were dissolved in DMSO to prepare stocks and were stored at -20o C until
use. Each of these compound’s chemical structures with names are shown in Table 4.1.
The compounds were named c1-c10 for sake of convenience.

4.3.3. Cell-based inhibition test of the lead compounds against ZIKV infection
To determine inhibitory effect of the compounds (c1-c10) on ZIKV replication,
we infected Vero cells with PRVABC59 ZIKV at an MOI of 1 followed by treatment of
the infected cells with 1 μM concentration of the compounds as shown in Fig. 4.4A. All
the compounds I tested did show some level of inhibition of ZIKV replication, however,
the compound c1, 3-chloro-N-[((4-[4-(2-thienylcarbonyl)-1-piperazinyl]phenyl)amino)
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Structure

Mol.
Weig
ht

Compound

Name

Score

c1

3-chloro-N-[((4-[4(2-thienylcarbonyl)1piperazinyl]phenyl)
amino)carbonothio
yl]-1benzothiophene-2carboxamide

541.10 −118.79
8
4

c2

N-(([4-(5,7dimethyl-1,3benzoxazol-2yl)phenyl]amino)ca
rbonothioyl)-3methyl-1benzofuran-2carboxamide

455.52
−118.36
8

c3

7-[4-(([3(ethoxycarbonyl)ph
enyl]amino)carbono
thioyl)-1piperazinyl]-1ethyl-6-fluoro-4oxo-1,4-dihydro-3quinolinecarboxylic
acid

525.57 −118.35
2
8

c4

2,2'-[(4,4'-diallyl4H,4'H-3,3'-bi1,2,4-triazole-5,5'diyl)bis(thio)]bis(1phenylethanone)

516.63 −118.09
8
7

c5

3(phenoxycarbonyl)b
enzyl 3-(5-phenyl1,3,4-oxadiazol-2yl)benzoate

476.48 −117.31
0
9

c6

2-[(5-([(4-amino-6,7dihydro-5Hcyclopenta[4,5]thieno[
2,3-d]pyrimidin-2yl)thio]methyl)-4phenyl-4H-1,2,4triazol-3-yl)thio]-Ncyclohexylacetamide

539.61

c7

N,N'-[(3-oxo-2,3dihydro-1Hisoindole-1,1diyl)di-4,1phenylene]bis(2phenylacetamide)

484.61 −115.82
8
3

−116.08
7
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c8

N-(([3-(3methyl[1,2,4]triazolo[3
,4-b][1,3,4]thiadiazol6yl)phenyl]amino)carbo
nothioyl)-1benzofuran-2carboxamide

471.59 −115.78
2
9

c9

2-([4-allyl-5-(2quinolinyl)-4H1,2,4-triazol-3yl]thio)-1-(1Hindol-3-yl)ethanone

471.57 −115.72
4
4

c10

N-(([5-(5-ethyl-1,3benzoxazol-2-yl)-2methylphenyl]amino)c
arbonothioyl)-1benzofuran-2carboxamide

482.44 −114.33
3
3

Table 4.1 Top ten compound’s chemical structures, names, molecular weight with
docking score.
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Fig. 4.4. Inhibition of ZIKV replication by the top 10 lead compounds. (A) Viral
genome copies in the supernatants of cells infected with PRVABC59 virus in the presence
of 1 μM concentration of the ten compounds (c1-c10) or with vehicle (No Drug) alone for
72 hr. The data are expressed as % of DMSO-treated control. The experiment was done
in triplicate and bars represent ± SEM. (B) Infectious virus titers in the supernatant of
cells infected with the virus and incubated with 1 μM concentration of the compounds or
with vehicle (DMSO) alone for 96 hr.
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carbonothioyl]-1-benzothiophene-2-carboxamide (TPB) exhibited the highest inhibitory
activity among the 10 lead compounds. While ZIKV growth was inhibited (Fig. 4.4A) (as
determined by genome copies in the culture supernatants) by ~1000-fold in cells treated
with c1 (TPB) compared to the vehicle-only treated cells, c6 and c10 also inhibited virus
growth by nearly 10-12 fold. Infectious virus yield was also inhibited by at least 1000fold in the presence of 1 μM TPB (Fig. 4.4B) whereas c6 and c10 inhibited virus growth
by nearly 10-fold at the same concentrations. Although all the compounds readily bound
to the target site as per in silico docking analysis, c1, c6, and c10 appeared to show
additional contacts with the priming loop as well as other regions in the RdRp target site
resulting in possibly stronger interactions and better binding (Fig. 4.5A and B). These
initial studies thus demonstrated that three compounds, c1, c6, and c10 exhibited
significant inhibitory activity on ZIKV growth under in vitro conditions, with c1 being
the most potent.

4.3.4. Characterization of compound 1 (TPB) interaction with RdRp
From molecular docking analysis, it appears that c1 (named TPB from here
onwards), interacts with residues in the target site of the ZIKV RdRp (Fig. 4.6A-C).
Three hydrogen bonds of TPB are in direct contact with two aspartic acid residues (D535
in motif A and D665 in motif C) in RdRp (Fig. 4.6A). Since these two aspartic acid
residues as well as D666 are highly conserved residues in the target and the active site of
all RdRps of flaviviruses and play critical roles in coordinating divalent metal ions
(Mg++), TPB could potentially be a highly promising anti-ZIKV as well as antiflavivirus drug candidate. So, from the initial cursory screening studies, TPB was shown
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Fig. 4.5. Docking of compounds c1-c10 in the catalytic cavity of the RdRp of ZIKV.
(A) The drug target site is marked by pink square box. The binding sites and the top 10
compounds are shown in ribbon (protein) and stick (drug) representation. (B) Close-up
view of stick representation of top 10 compounds within the RdRp target site. The image
was generated by PyMol.
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Fig. 4.6. Interaction of TPB with the residues within the target site of RdRp. (A)
Structure of ZIKV RdRp generated by homology modeling. The three subdomains are
colored separately: fingers (cyan), thumb (blue), and palm (red). The catalytic active site
and the priming loop are labeled. Docking of TPB on the active site of RdRp and the
contacts with the two aspartic residues (D535 and D665) along with the three hydrogen
bonds are indicated. A magnified view of the target site with TPB is shown on the right.
The hydrogen bonds (dashed lines) and the two aspartic acid residues are identified. (B)
The chemical structure of TPB (molecular weight of 541.108 Da). (C) The space-filing
model of the boxed area in A is shown along with the bound TPB. TPB binding at the
palm subdomain is shown.
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to inhibit ZIKV replication significantly.

4.3.5. TPB inhibits ZIKV replication in a dose-dependent manner
We then tested the inhibitory activity of TPB in a dose-dependent manner in the
μM range. Vero cells were infected with ZIKV at an MOI 1 and treated with different
concentrations (0, 0.5, 1, 2, 4, 8 and 16 M) of TPB for 96 hr. Culture supernatants were
then examined for viral genome copy numbers as well for infectious progeny. The results
showed that even at 0.5 μM concentration of TPB, significant inhibitory activity against
ZIKV replication was observed. Both genome copy numbers (Fig. 4.7A) and infectious
virus (Fig. 4.7B) in the supernatants were reduced by over 100-fold at this concentration
of TPB. Although TPB at 1 μM reduced virus growth by over 1000-fold, further increase
in TPB concentration did not result in further inhibition.

4.3.6. Inhibition of ZIKV protein synthesis by TPB
Since TPB inhibits ZIKV virus replication significantly in cell based assay, we
investigated to find out if the inhibitory effect of TPB on ZIKV replication is due to
lower viral protein expression in infected cells. We examined the expression levels of E
in ZIKV infected cells by western blotting. The ZIKV genome is translated into a single
polypeptide which is cleaved to yield 3 structural and 7 non-structural proteins. We chose
to look for the expression of E protein since the E protein antibody was readily available.
Vero cells were infected with PRVABC59 virus at an MOI 1 and the cells were treated
with 0, 0.5, 1, 2 M concentrations of TPB for 48 hr. Cell lysates were assessed for viral
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Fig. 4.7. Validation of the antiviral effect of TPB. Cells infected with PRVABC59 virus
were incubated in the presence of various concentrations of TPB for 96 h. Culture
supernatants were titrated for viral genome copies (A) and infectious virus (B). Data are
from three independent experiments with error bars showing ± SEM. Statistical analysis
was performed using unpaired two-tailed Student'st-test to determine significance of
difference. ****, p≤ 0.0001.
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E protein levels. Results show that the levels of E protein is significantly reduced at 0.5
μM TPB and was undetectable at higher concentrations (Fig. 4.8). These results suggest
that TPB inhibits viral protein expression in infected cells.

4.3.7. The growth of the original isolate (MR766) of ZIKV is also inhibited by TPB
Since we used a contemporary isolate of ZIKV (PRVABC59, isolated from a
patient in Puerto Rico in 2015) in our initial studies, we wanted to determine if TBP also
has antiviral activity against the historical isolate of the virus. In this study, Vero cells
were infected with the historical strain of ZIKV, MR766 (isolated in Uganda), at an MOI
1 and treated with different concentrations of TPB for 96 hr. As control, we similarly
infected cells with PRVABC59 virus and treated with the same concentrations of TPB.
The culture supernatants were collected after 96 hours of infections and assayed for
infectious progeny production. Results demonstrated that the MR766 isolate was also
inhibited by TPB at the concentrations tested (Fig. 4.9A). The extent of MR766 virus
growth inhibition appeared to be similar to that of the PRVABC59 virus (Figs. 4.9B).
Overall, it appears that maximal ZIKV growth inhibition by TPB could be achieved at 12 μM concentrations and further increase had no significant inhibitory effect, indicating
that the TPB inhibitory target is saturable at these concentrations. The results show that
both the contemporary and historical isolates of ZIKV are equally inhibited by TPB.

4.3.8. TPB inhibits ZIKV growth in physiologically relevant cell line
Initially all our experiments were conducted using Vero cells. We sought to test
whether TPB can inhibit ZIKV replication in physiologically relevant cell lines. ZIKV
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Fig. 4.8. Western blot analysis of E protein expression in the presence of TPB. Vero
cells were infected (Virus-Inf) with PRVABC59 virus or mock-infected (Mock-Inf) and
subsequently incubated in the presence of various concentrations of TPB. Cell extracts
were examined for E protein expression. Relative mobility of molecular mass markers (in
kilodaltons) is shown on the left.
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Fig. 4.9. TPB inhibits both African and Asian strains of ZIKV. Cells infected with
MR766 (African) or PRVABC59 (Asian) strains of the virus were incubated in the
presence of various concentrations (0, 0.5, 1, and 2 µM) of TPB for 96 h. Culture
supernatants were titrated by plaque assay. Infectious virus titer of MR766 (A) and
PRVABC59 (B) virus. Data are from three independent experiments with error bars
showing ± SEM. Statistical analysis was performed using unpaired two-tailed Student's ttest to determine significance of difference. ****, p≤ 0.0001.
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has a broad tissue tropism in humans and is known to interact with various cell surface
receptors which contributes to its wide cell tropism (Hamel et al., 2015), which in turn
may contribute to the clinical manifestation of congenital neurological disorders in
infants. ZIKV is known to be transmitted sexually in humans (Allard et al., 2017).
Vertical transmission from mother to fetus is also reported (Ciota et al., 2017). Therefore,
we choose two cell lines from the human reproductive system, HTR-8 (human
trophoblast cell line), and NTERA (human testicular cell line), and SH-SY5Y
(neuroblastoma cell line) to check the effect of TPB. A previous study from our lab has
shown that the above mentioned cells are permissive to ZIKV infection (Annamalai et al.,
2017). My results show that TPB significantly inhibits the virus growth in HTR-8,
NTERA, and SH-SY5Y (Figs. 4.10A-C) similar to what was seen in Vero cells.
Therefore, our results show that not only TPB inhibits ZIKV growth in Vero cells, but it
also inhibits virus growth in several other physiologically relevant cell lines.

4.3.9. Determination of cellular cytotoxicity 50 (CC50) of TPB
Low cytotoxicity is an essential requirement for drug development. It would also
suggest whether the drug's inhibitory effect is independent of cellular cytotoxicity due to
the presence of the drug. Therefore, we performed a cell viability assay to determine the
cellular cytotoxicity 50 (CC50) concentration of TPB. Vero cells were exposed to
increasing concentrations of TPB (0.1 M to 32 M) and incubated for 96 hr.
Subsequently, an ATP-based assay was conducted to determine cell viability and the
results showed that cell viability was >95% in the presence of up to 12 M TPB and
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Fig. 4.10. TPB inhibits ZIKV replication in physiologically relevant cell lines. Cells
infected with PRVABC59 virus were incubated in the presence of various concentrations
(0, 0.5, 1 µM) of TPB for 96 h. Culture supernatants were titrated by plaque assay for
infectious virus titers and expressed as PFU/ml. Virus titers in HTR-8 cell line (A), in
NTERA cell line (B), and in SH-SY5Y cell line (C). Data are from three independent
experiments with error bars showing ± SEM. Statistical analysis was performed using
unpaired two-tailed Student'st-test to determine significance of difference. ****, p≤
0.0001.
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further increase in TPB concentration resulted in a gradual loss of viability (Fig. 4.11A).
The CC50 value for TPB was calculated to be 19.4 μM (Fig. 4.11A).

4.3.10. Inhibitory concentration 50 (IC50) determination
To characterize the anti-ZIKV potency of TPB, we conducted studies to
determine the inhibitory concentration 50 (IC50). We used serial 2-fold dilutions of TPB,
and treated Vero cells infected with PRVABC59. The culture supernatants were assayed
for infectious virus by plaque assay and expressed as % virus yield relative to the virus
yield without TPB. The data were statistically analyzed and the IC50 concentration was
determined to be about 94 nM (Fig. 4.11B). The IC50 value of TPB in the 10-100 nM
range also suggests that TPB is a strong inhibitor of ZIKV and a potential drug candidate
for further development. The selectivity index 50 (SI50 = CC50/IC50) was calculated to be
206. This high SI50 also suggests that TBP is not only a potent inhibitor of ZIKV at
submicromolar concentrations but is also nontoxic to the cells.

4.3.11. Comparison of TPB with other known inhibitors of ZIKV
To further compare the potency of TPB relative to other reported ZIKV inhibitors,
we examined two compounds that have been recently shown to inhibit ZIKV replication.
Mycophenolic acid (MPA) is an immunosuppressant drug and is used to prevent rejection
in organ transplantation and was shown to inhibit DENV RNA replication (Diamond et
al., 2002). In a screen of FDA-approved drugs for inhibition of ZIKV infection, MPA at 1
μM was found to inhibit infection of cells in vitro by ZIKV by over 99% (Barrows et al.,
2016). Likewise, ivermectin (IVM), an anti-parasitic drug (Omura and Crump, 2017),
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Fig. 4.11. Determination of CC50 and IC50 of TBP. (A) Vero cells were treated with
TPB at various concentrations for 96 hr and cell viability was measured based on ATP
assay. The luminescence signals were measured at 420 nm using a Microplate
Luminometer. Non-linear regression analysis of the data was employed to determine the
CC50. (B) For determination of IC50 value of TBP, Vero cells were infected with
PRVABC59 virus at an MOI of 1 and incubated with various concentrations of TPB as
shown. Infectious virus titers in the supernatants of the cells at 96 h post-infection were
determined by plaque assay and virus yield was expressed as % of TPB-untreated
control. Non-linear-regression was employed to determine the IC50.
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which also inhibits YFV infection (Mastrangelo et al., 2012), was found to inhibit ZIKV
infection strongly at 10 μM (Barrows et al., 2016). A side-by-side comparison of the
inhibitory potency of TPB with MPA and IVM shows that while TPB inhibited ZIKV
yield by over 1000-fold, MPA and IVM inhibited virus yield by approximately 10- to 20fold (Fig. 4.12). These results suggested that TPB is more potent in inhibiting ZIKV as
compared to MPA or IVM.

4.3.12. Pharmacokinetic of TPB in vivo
Since TPB was found to be a potent inhibitor of ZIKV replication in vitro, we
wanted to examine if it also inhibits virus replication and viremia in mice. Therefore, we
first conducted a pharmacokinetics (PK) analysis of TPB in immunocompetent BALB/C
mice to examine the stability and in vivo retention of the drug. BALB/C (n=18) were
divided into two groups. One group (n=9) was injected with TPB intraperitoneally (IP) at
5mg/kg body weight and the other group (n=9) injected with a dose of 25mg/kg body
weight. Blood collection was done every 2 hr to evaluate plasma concentrations of TPB.
The results of the PK studies show that TPB is retained in the plasma at approximately
500 ng/ml (corresponding to a concentration of approximately 1 μM) in the initial 2 hr
post injection and is gradually reduced to ~100 ng/ml (approximately 0.2 μM
concentration) in the next 10-12 hrs at the two doses tested (Fig. 4.13).

4.3.13. Antiviral activity of TPB in vivo
We next tested whether administration of TPB into immunocompetent mice
would result in reduced levels of ZIKV viremia. Although immunodeficient mice models
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Fig. 4.12. Comparison of TPB inhibitory activity with mycophenolic acid (MPA)
and ivermectin (IVM). Vero cells were infected with PRVABC59 virus at an MOI 1 and
incubated with TPB (1 μM), MPA (1 μM), or IVM (10 μM). Culture supernatants were
collected at 96 h post-infection and assayed for infectious virus. Data presented are from
three independent experiments with error bars showing ±SEM. Statistical analysis was
performed using unpaired two-tailed Student’s t-test to determine significance of
difference. ***, p ≤ 0.001; ****, p ≤ 0.0001.
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Fig. 4.13. Pharmacokinetics (PK) analysis of TPB in mice. BALB/C mice were
divided into two groups. Intraperitoneally, mice in one group (n=9) were injected with
TPB (5 mg/kg body weight) while mice in the other group (n=9) were injected with a
dose of 25 mg/kg body weight. At every 2 hr intervals, blood was collected from these
animals to measure plasma concentrations of TPB. Analysis was done by LC-MS/MS.
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have been developed to study ZIKV pathogenesis and drug development (Julander et al.,
2017; Lazear et al., 2016; Rossi et al., 2016a; Zmurko et al., 2016), less expensive
immunocompetent mice models with limited clinical manifestations have also been used
to examine viremia in vaccine studies (Larocca et al., 2016). Based on non-compartment
analysis of the pharmacokinetics data, it was estimated that steady-state levels > 500
ng/ml of TPB (∼1 μM) could be achieved with three injections at twelve hour intervals at
25 mg/kg dose of TPB in mice. To examine the effect of the drug on ZIKV growth in
mice, groups of mice (n = 6) were first injected intraperitoneally with the drug at 25
mg/kg dose and subsequently infected with 500 PFU of ZIKV subcutaneously (Fig.
4.14A). Two more doses of the drug were injected at 0 hr and 12 hr following virus
infection. Virus load in the plasma of the animals on days 2, 3, 4, 5, and 6 post-infection
was determined. Results of virus growth (genome copies in the serum) in individual
animals showed that these immunocompetent mice supported transient ZIKV growth that
could only be detected on day 4 (Fig. 4.14B). The level of viral RNA detected on day 4
post-infection was nearly 40-fold lower in mice injected with the drug as compared to the
group injected with the vehicle (5% dextrose) alone (Figs. 4.15A). The transient nature of
viremia in these animals has also been noted previously (Larocca et al., 2016; Yu et al.,
2017). We also examined for the plasma concentration of TPB on 0, 1, and 2 days postinfection and it was found to be on average ~270 ng/ml in the animals on day 2 (Fig.
4.15B). Although this level of TPB was not optimal for maximal virus growth inhibition
as observed under in vitro conditions, the results suggested that TPB exerts significant
growth inhibition of ZIKV in vivo.

115

Fig. 4.14. Efficacy of TPB in mice. (A) Schematic diagram showing the experimental
plan. BALB/C mice were divided into two groups. Twelve hours prior to virus infection,
mice in one group were injected with TPB (25 mg/kg) while mice in the other group were
injected with the vehicle (DMSO). All mice were infected subcutaneously with 500 PFU
of ZIKV per mouse followed by two additional intraperitoneal injections of TPB at the
same dose or DMSO at 0 and 12 hrs after virus infection. (B) Genome copies at various
days post-infection in the plasma of individual mice treated without (continuous lines) or
with (discontinuous lines) TPB.
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Fig. 4.15. Inhibitory efficacy of TPB in mice. (A) Data from the mice groups in Fig.
14B. Error bars show ±SEM. Statistical analysis was performed using unpaired twotailed Student’s t-test to determine significance of difference. ****, p ≤ 0.0001. (B) TPB
mean concentrations in mice plasma (from Fig. 14B) at various days post-injection. Error
bars show ±SEM.
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4.4. Discussion
Through in silico screening of a library of 100,000 small molecules, we identified
TPB as a potential anti-ZIKV drug candidate. Subsequent in vitro and in vivo studies
demonstrated that TPB exhibits potent inhibitory activity against ZIKV at submicromolar
concentrations. The inhibitory activity was shown to be against both the African and
Asian genotypes representing the historical and contemporary isolates of the virus. In
addition, the inhibitory effect of TPB is cell-type independent at least in the cells tested in
this study. The IC50 and CC50 of TPB were determined to be 94 nM and 19.4μM,
respectively, yielding an SI50 value of over 200. Such high SI50 value suggests that TPB
has a strong potential for an effective anti-ZIKV drug with little to no cytotoxicity.
TPB is a non-nucleoside compound which makes it more valuable in the drug
development field since non-nucleoside inhibitors (NNI) of viral RdRps are considered to
inhibit through allosteric effect by blocking RNA replication/transcription. Thus, they are
more selective for viral targets only and with significantly less side-effects (Lim et al.,
2015; Malet et al., 2008). Furthermore, since TPB was docked to the active site of the
ZIKV RdRp forming three hydrogen bonds in direct contact with two aspartic acid
residues (D535 in motif A and D665 in motif C) in RdRp (Fig. 4.5A and 4.6A), it makes
this compound a promising anti-ZIKV drug candidate. The aspartic acid residues
(D535/D665 or D535/D665/D666) are highly conserved in the active sites of all RdRps
of flaviviruses and play essential roles in coordinating with two divalent metal ions
(Mg++) for initiation of ribonucleotide polymerization (Butcher et al., 2001; Choi and
Rossmann, 2009; Duan et al., 2017; Godoy et al., 2017; Ng et al., 2008; Yap et al., 2007;
Zhao et al., 2017). The binding of TPB to these active site residues and possibly blocking
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of this active site are likely very efficient, which may likely explain the potent inhibitory
activity of TPB at submicromolar concentrations. However, in vitro binding of the
polymerase with TPB leading to inhibition of RdRp activity needs to be validated
experimentally. Additionally, the binding of TPB to NS5 may alter its interaction with
other NS proteins involved in virus genome replication leading to inhibition. Future
studies will reveal the mechanism of inhibition of NS5 function by TPB.
We have evaluated TPB toxicity in terms of cell viability using ATP-based assays
and found no cellular toxicity. When TPB was administered at 25 mg/kg dose, all mice
appeared normal over a six-day period. However, if TPB is to be tested for its potential
use as a drug candidate, detailed investigation needs to be conducted to assess its toxicity
in vivo. Since the ZIKV RdRp model used in this research was generated from homology
modeling using the DENV-3 RdRp structure, it is presumed that TPB and other lead
compounds could be tested for anti-DENV activity. Additionally, because ZIKV RdRp aa
sequence is closest to JEV EdRp (Lu and Gong, 2013; Upadhyay et al., 2017), it is
possible that TPB could also be effective against JEV. Although there are some observed
structural differences such as in the Ring motif F, the active site is highly conserved in
the flavivirus RdRps. Of special note here are the two aspartic acid residues (D535/D665)
that are present in the catalytic pocket of RdRp that provide a foundation for TPB
binding.
In conclusion, through the in silico screening approach, we have identified a nonnucleoside compound, TPB, which shows a potent inhibitory activity against ZIKV
infection in vitro as well as in vivo. TPB is a novel non-nucleoside inhibitor targeting the
active site of ZIKV and likely other flavivirus RdRp.
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CHAPTER V: INHIBITION OF ZIKV REPLICATION BY G-QUADRUPLEXBINDING LIGANDS

Part of the studies described in this chapter was published in Molecular Therapy:
Nucleic Acids, 2021
Majee, P., Pattnaik, A., Bikash R. Sahoo, Uma Shankar, Asit K. Pattnaik, Amit Kumar,
and Debasis Nayak (2021). Inhibition of ZIKV replication by G-quadruplex- binding
ligands. Molecular Therapy: Nucleic Acids Vol. 23, 691-701.
doi.org/10.1016/j.omtn.2020.12.030
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5.1. Abstract
In recent years, the presence of non-canonical G-quadruplex (GQ) secondary
structures in viral genomes has ignited significant attention as potential targets for antiviral strategy. In this study, we identified several novel conserved potential GQ structures
by analyzing published ZIKV genome sequences. Whether these potential GQ structures
do actually exist in the genome of ZIKV and whether they play any role in the viral
genome replication were addressed in experiments reported here. Bio-physical and
biochemical analysis of the RNA sequences suggested the existence of GQs in the ZIKV
genomes. Studies with known GQ structure-binding and -stabilizing ligands such as
Braco-19 and TMPyP4 provided further support for this contention. In cells infected with
ZIKV, the presence of these ligands in culture media led to significant inhibition of
infectious ZIKV yield. Furthermore, viral genome replication as well as viral protein
production were significantly downregulated in the presence of these drugs. Overall, our
results, for the first time, show that ZIKV replication can be inhibited by GQ structurebinding and -stabilizing compounds. Results from our studies will greatly expedite
research on the use of GQ-binding ligands as potential therapeutics against ZIKV
replication for mitigation and control of infections.

5.2. Introduction
As there are no effective licensed vaccines or drugs currently available, various
strategies and approaches are being explored for the development of vaccines and
antiviral drugs against ZIKV. These include targeting viral proteins (structural and nonstructural) for vaccine development and repurposing of the already approved antivirals
and/or anticancer drugs (Zou and Shi, 2019) as potential antivirals. Further research on
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alternate strategies for the discovery of new and effective antiviral compounds is
warranted. In the previous chapter of this thesis, we explored the possibility of using the
viral RdRp as the target to identify and characterize a non-nucleoside inhibitor of the
virus replication. In this chapter, we target the viral genome structural features for the
purpose of developing an antiviral strategy.
As outlined in the introductory chapter of this thesis, the G-quadruplex (GQ)forming sequences are being explored extensively as drug targets and have gained
significant attention as potential antiviral strategies in recent years (Lavezzo et al., 2018;
Ruggiero and Richter, 2018). Several viruses including SARS-CoV-2 (Cui and Zhang,
2020), ZIKV (Fleming et al., 2016), human papillomaviruses (HPV) (Tluckova et al.,
2013) herpes simplex virus (HSV) (Artusi et al., 2015) and human immunodeficiency
virus (HIV) (Piekna-Przybylska et al., 2014) are reported to bear GQ-forming sequences
in their genome. Furthermore, the GQ-binding ligands such as Braco-19 and coreextended naphthalene diimides (NDI) have been shown to have a significant antiviral
effect on HIV replication (Perrone et al., 2014; Perrone et al., 2015). Another potent GQbinding ligand, TMPyP4, was found to stabilize the GQ structure in the Ebola virus
polymerase (L) gene, thereby repressing its expression at the RNA transcription level
(Wang et al., 2016b). A similar effect of TMPyP4 was also observed in the case of the
core gene of hepatitis C virus (HCV) (Wang et al., 2016a). These studies provide a
framework for further research on the potential use of GQ-binding and -stabilizing
ligands for antiviral strategies (Lavezzo et al., 2018; Ruggiero and Richter, 2018).
In a recent report (Fleming et al., 2016), it was first shown that putative GQforming sequences are present in the ZIKV genome that are largely conserved among the
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Flaviviridae family, although the functional consequences of the presence of such
structures were not examined by the authors. In this study, we have discovered a number
of additional GQ-structure-forming sequences that are unique ZIKV in addition to those
reported by Fleming et al. Taking ZIKV genomic RNA sequences carrying several of
these potential GQ structures, and by using various assays such as fluorescence titration
assay, nuclear magnetic resonance (NMR) spectral analysis, isothermal titration
calorimetric (ITC) assay, and thermal denaturation experiments, our research
collaborators in India demonstrated that (1) the GQ structures do in fact exist in these
RNA sequences, and (2) that the GQ-binding ligands such as Braco-19 and TMPyP4 bind
specifically to these structures and stabilize them. Extending those observations, we
conducted studies to show here that treatment of ZIKV-infected cells with these ligands
results in significant reduction in infectious virus production, as well as inhibition of viral
genome replication and viral protein production in a dose-dependent manner. Thus, GQligand binding strategy displayed in this study stands as a proof of concept and appears
promising toward the development of potential antiviral agents against ZIKV infection.

5.3. Results
5.3.1. ZIKV genome has potential GQ structures conserved across the strains
In a previous study, it was reported that Flaviviruses including the ZIKV contain
conserved GQ-forming sequences (Fleming et al., 2016). By employing stringent criteria
where the number of guanine repeat was kept ≥2 and the loop length was restricted
between 1 and 7 nucleotides, we identified four new ZIKV GQs (ZGQ1-4) conserved in
the NS genes NS2, NS4B, and NS5 genes of ZIKV genome (Fig.5.1A) in addition to the
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Fig. 5.1. G-quadruplex (GQ) structures are highly conserved in ZIKV genome. (A)
Schematic diagram showing the location of the GQ sequences predicted in the ZIKV
genome. Seven GQ sequences are distributed in the NS genes, namely, NS2, NS3, NS4B,
and NS5, and one in the 3’ UTR region. (B) WebLogo representation of the four newly
predicted ZGQ sequences (ZGQ1-4) showing conservation of the nucleotides among
various strains. The height of the letter indicates the relative frequency of that particular
nucleotide at that position, therefore reflecting the degree of conservation at that position.
(C) WebLogo representation of the predicted GQ sequences showing conservation of the
nucleotides among different strains in the anti-genomic (negative-sense) RNA.
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other ZGQs (ZNS3, ZNS4, ZNS5A, and ZNS5B) identified previously (Fleming et al.,
2016). Importantly, the genome-wide mining of 247 ZIKV genomes from the NCBI
Genome database revealed that these newly identified ZGQs are highly conserved among
>90% of the ZIKV strains (Majee et al., 2021) (Fig. 5.1B). As displayed in Fig. 5.1B, the
WebLogo representation of the newly predicted four ZGQ sequences suggests that the
guanine residues involved in the GQ formation are highly conserved among the analyzed
strains. The residues present in the loop region are mostly divergent. Because ZIKV is an
RNA virus, it is prone to a higher mutation rate (Duffy, 2018); thus, the conservation of
these ZGQs across the isolates suggests functional importance of these sequences
associated with viral life cycle and pathogenesis. Since ZIKV replication occurs through
anti-genomic (negative-sense) RNA intermediates, we also examined the presence of
ZGQs in the negative-sense RNA. Our search identified several highly conserved ZGQ
sequence motifs (AS-ZGQs) in the viral anti-genomic (negative-sense) RNA (Majee et
al., 2021) (Fig. 5.1C).

5.3.2. ZIKV growth is inhibited in vitro in the presence of GQ-binding compounds
Braco-19 and TMPyP4
Biophysical and biochemical characterization of ZGQ1-4 by our collaborators
suggested that the predicted ZGQ in ZIKV genome can fold into GQ structures that are
be stabilized through the binding of Braco-19, as well as TMPyP4. To determine whether
the presence of such structures and stabilizing them through binding with Braco-19 could
impact ZIKV growth in cultured cells, we performed experiments to assess ZIKV growth
in Vero cells in the presence of varying concentrations of the drug. Vero cells infected
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with MR766 isolate of ZIKV were treated with Braco-19 and infectious virus yield in the
supernatants at various time points was measured by plaque assay. In response to Braco19 treatment, the infectious virus yield showed a significant reduction in a dosedependent manner, at each of the time points examined. The inhibition of virus growth
was most significant at 96 hpi in the presence of 100 M concentration of Braco-19,
compared to the untreated control (Fig. 5.2A). At lower concentrations (1 M and 10
M), although we reproducibly observed 3-5 fold less infectious
virus compared to untreated controls at all the time points examined, they were not
statistically different from the untreated control.
In a similar experiment using a different GQ-binding and -stabilizing drug
TMPyP4, we observed that ZIKV growth was also significantly inhibited (Fig. 5.2B). At
a concentration of 10 M, the infectious virus yield in the supernatants at 72 hpi and 96
hpi was reduced nearly 120-fold and 170-fold, respectively, compared to the untreated
control (Fig. 5.2B). However, at 100 M concentration, the infectious virus yield in the
supernatant was below the limit of detection at any of the time points studied (Fig. 5.2B).
To determine inhibition of viral replication was due to binding of the drug to GQ
structures and not to drug-dependent cytotoxicity, we performed a cell viability assay.
This experiment allowed me to determine the overall health of cells in the presence GQ
binding ligands. We treated Vero cells with 0, 1, 10 and 100 M concentrations of Braco19 or TMPyP4 for 4 days. Four independent experimental replicates with the above
mentioned concentrations were done for both the compounds. Four days after drug
treatments, cell viability was determined by flow cytometry analysis. In the presence of
100 M concentration of Braco-19, where virus growth was inhibited by > 80-fold, cell
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Fig. 5.2. Inhibition of ZIKV growth in cells treated with Braco-19 and TMPyP4.
Vero cells infected with ZIKV at an MOI of 1 were incubated in medium containing 0
(untreated), 1 M, 10 M, and 100 M concentrations of Braco-19 (A) or TMPyP4 (B).
Aliquots of culture supernatants were collected at various hour post-infection (hpi) and
infectious virus titers were determined by plaque assay. The graphs show mean values of
virus titers, with error bars representing standard deviations from the results of four
independent experiments. Two-way ANOVA was used to determine significant
differences in virus titers between untreated and drug-treated samples. LOD, the limit of
detection. # represents values below LOD. ns, nonsignificant; ***p ≤ 0.001; ****p ≤
0.0001
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viability was greater than 85% (Fig. 5.3). Unlike Braco-19, TMPyP4 was toxic at 100
M and cell viability was ~40% (Fig.5.3); however, at 1 M and 10 M concentrations
where ZIKV growth inhibition was significant, cell viability was shown to be over 85%.
Overall, these results show that both Braco-19 and TMPyP4 inhibit ZIKV growth at
concentration which are not toxic to the cells and suggest that these GQ-binding ligands
directly inhibit ZIKV growth without adversely affecting cell viability.

5.3.3. Intracellular accumulation of infectious virus is not significantly different in
the presence or absence of Braco-19 or TMPyP4
It is possible that lower levels of infectious virus in the culture supernatants of
infected cells in the presence of Braco-19 and TMPyP4 could be due to increased
accumulation of intracellular virus. To investigate such a possibility, we determined the
amount of virus present in the cells. For this, following infection of cells in the presence
of the drugs for 72 hours, we collected the culture supernatants, washed the cells with
PBS and then subjected the cells to three rounds of freeze-thaw in the presence of PBS to
break open the cells and release cell-associated virus, after which the clarified cell
extracts were assayed for infectious virus by plaque assay. As can be seen (Fig. 5.4), on
average, cell-associated virus represented about 17-fold less than the virus released in the
supernatants of infected cells under no-drug treatment condition at 72 hpi. In the presence
of 100 M Braco-19 or 10 M TMPyP4, cell-associated virus represented approximately
14- to 15-fold less than that in the corresponding supernatants. Importantly, the cellassociated virus in drug treated cells were significantly lower than those in untreated cells
(Fig. 5.4). These results show that both Braco-19 and TMPyP4 inhibit infectious ZIKV
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Fig. 5.3. Cell viability in the presence of Braco-19 and TMPyP4. Vero cells were
exposed to 0, 1, 10, and 100 M Braco-19 or TMPyP4 for 4 days. Following exposure,
the cells were trypsinized and stained with mBCl and propidium iodide (PI) to measure
cell viability and total cell number. Flow cytometric data acquisition was performed using
a BD Cytek flow cytometer (Becton Dickinson, Franklin Lakes, NJ) in the VioFL1 and
BluYeFL3 channels and data analysis was done using FlowJo software (Becton
Dickinson, Franklin Lakes, NJ).
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Fig. 5.4. Inhibition of ZIKV progeny virus production in cells treated with Braco-19
and TMPyP4. Vero cells were infected with ZIKV at an MOI of 1 and treated with 100
M Braco-19 or 10 M TMPyP4 for 72 hpi. Infectious virus in the supernatants and cells
were quantitated by plaque assay. The graphs show mean values of virus titers, with error
bars representing standard deviations from the results of three independent experiments.
Two-way ANOVA was used to determine significant differences in virus titers between
untreated and drug-treated samples. **p ≤ 0.01; ***p ≤ 0.001
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progeny production.

5.3.4. ZIKV viral protein synthesis is inhibited by Braco-19 and TMPyP4
Since Braco-19 and TMPyP4 treatment reduced infectious ZIKV yield, we next
sought to find out whether this is due to lower viral protein expression in infected cells.
We examined the E protein expression levels in virus-infected cells in the presence of
Braco-19 or TMPyP4. Since the ZIKV genome is translated into a single large
polyprotein, which is processed to yield 10 different proteins including the E protein, we
picked the E protein as indicator viral protein production. Vero cells, infected with
MR766 ZIKV, were treated with varying concentrations of Braco-19 or TMPyP4
immediately after infection. Cell lysates were prepared from the infected cells at 48 or 96
hpi and analyzed for E protein levels by western blotting. Results showed a marked
reduction in E protein expression with increasing concentrations of Braco-19 at both 48
hpi and 96 hpi (Fig. 5.5 A-B). The reduction of E protein levels was most pronounced at
100 M Braco-19 and at 96 hpi, although reduction in the levels of E was reproducibly
seen at lower concentrations.
In response to TMPyP4 treatment, E protein levels showed noticeable reduction
over time (Fig. 5.6A-B). Interestingly, the electrophoretic mobility of the E protein was
altered at 48 hpi time point (Fig. 5.6A), with increasing dose of TMPyP4, resulting in
apparently increased molecular mass of the E protein. However, at 96 hpi, the reduced
electrophoretic-mobility of E was only observed with 100 M TMPyP4 (lane 5, Fig.
5.6B) and the mobility difference was less pronounced compared to Braco-19. The reason
for the observed electrophoretic mobility shift in E protein in the presence of TMPyP4 is
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Fig. 5.5. Braco-19 inhibits viral protein synthesis. Vero cells were either mock-infected
or infected with ZIKV at an MOI of 1 and subsequently incubated in medium containing
0, 1 M, 10 M, and 100 M concentrations of Braco-19. Cell extracts were prepared at
48 hpi (A) and 96 hpi (B). Twenty g of proteins from each sample were analyzed by
SDS-PAGE and western blotting with ZIKV E antibody to detect viral E protein. Levels
of actin detected in the blots using anti-actin antibody served as the loading control.
Molecular mass markers (in kDa) are shown on the left. Representative data are shown in
each panel.
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Fig. 5.6. TMPyP4 inhibits viral protein synthesis. Vero cells were either mock-infected
(M) or infected with ZIKV at an MOI of 1 and subsequently incubated in medium
containing 0, 1 M, 10 M, and 100 M concentrations of TMPyP4. Cell extracts were
prepared at 48 hpi (A) and 96 hpi (B). Twenty g of proteins from each sample were
analyzed by SDS-PAGE and western blotting with ZIKV E antibody to detect viral E
protein. Levels of actin detected in the blots using anti-actin antibody served as the
loading control. Molecular mass markers (in kDa) are shown on the left. Representative
data are shown in each panel.
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unclear at this time but it is possible that metabolic byproducts of TMPyP4, known to be
generated in cells could bind to the E protein in a time- and concentration-dependent
manner to reduce the mobility of the E protein. Nevertheless, our results suggest that both
Braco-19 and TMPyP4 inhibit viral protein expression in infected cells.

5.3.5. ZIKV genome replication is inhibited by Braco-19 and TMPyP4
Since the GQ binding ligands directly target the GQ structures in the viral
genomic and anti-genomic RNAs, these drugs are likely to impede progress of the viral
RdRp during genome replication and ribosomal movement during translation. As we
have already demonstrated reduction in viral protein levels in the presence of these
ligands, we next sought to determine whether intracellular replication of the ZIKV
genome is negatively affected by the GQ-binding ligands. Vero cells, infected with ZIKV
MR766, were treated with Braco-19, TMPyP4, or left untreated and total RNA from the
cells was extracted at 72 and 96 hpi. Total RNA was subjected to qRT-PCR with ZIKVspecific primers and probes to determine the copy numbers of the viral positive-sense
genome. In these experiments, we used 100 M Braco-19 and 10 M TMPyP4 because
these concentrations of the ligands exhibited maximum inhibition without adversely
affecting cell viability. Results from the experiment showed that ZIKV genome copies
were significantly lower in cells treated with Braco-19 or TMPyP4 at both 72 and 96 hpi
(Fig. 5.7), suggesting that these GQ-binding molecules inhibit ZIKV genome replication
in infected cells.

5.4. Discussion
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Fig. 5.7. Braco-19 and TMPyP4 inhibit ZIKV genome replication. Levels of viral
genome in the presence of Braco-19 or TMPyP4. Vero cells infected with ZIKV at an
MOI of 1 were incubated in medium without drug (untreated) or in medium containing
100 M Braco-19 or 10 M TMPyP4. Viral genome copies in the cells at 72 and 96 hpi
were quantitated and expressed as copies per mg of total cellular RNA from the cells. The
graphs show mean values of genome copy numbers with error bars representing standard
deviations from the results of three independent experiments. Two-way ANOVA was used
to determine significant differences between untreated and drug-treated samples. ***p ≤
0.001; ****p ≤ 0.0001
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Due to the unavailability of commercial vaccines or antiviral drugs, control and
mitigation strategies for ZIKV infection remain a huge challenge to date. The
unpredictable nature of ZIKV outbreaks and the global prevalence of its arthropod vector
have further worsened the situation. Although attempts to repurpose the drugs like
Sofosbuvir, (Barrows et al., 2016), Niclosamide (Xu et al., 2016) and Galidesivir (Lim et
al., 2017) have shown pronounced anti-Zika activity, these drugs also come with certain
shortcomings such as poor bioavailability, poor liberation, and improper mode of
administration. If infection takes place during pregnancy, ZIKV can cause detrimental
effects on the fetus and eventually on the newborn. Prognosis of newborn babies infected
with ZIKV is unfavorable and infections could lead to permanent congenital defects.
Thus, utmost precaution and precision should be taken while strategizing therapeutic
countermeasures against ZIKV infection.
In recent years, GQ structures, which are non-canonical nucleic acid secondary
structures, are being discovered in almost all organisms including many viral genomes
and thus have been considered as potential targets for antiviral strategies (Ruggiero and
Richter, 2018). ZIKV and other Flaviviruses have been reported to possess conserved GQ
structures (Fleming et al., 2016). By expanding the analysis to all the available ZIKV
genome sequences published in the NCBI Genome database and employing an in-house
algorithm (Mishra et al., 2016), we were able to predict four additional highly conserved
GQ structures in ZIKV. Some GQ-forming sequences were also found to be conserved in
the anti-genomic strand of the ZIKV. However, further studies will be required to
validate whether the predicted GQs in the anti-genomic RNA actually form GQs. The
current study mainly focused on the GQ structures formed in the genomic RNA (positive-
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sense) of the ZIKV. The observation that these GQ structures are highly conserved
suggested to us that they may play a specific role in the life cycle and/or pathogenesis of
the virus. Two of the GQs were found to be located in the coding region of NS5 gene,
i.e., the RNA-dependent RNA polymerase coding gene, while the other two were present
in the NS2 and NS4B genes. These GQs were characterized by CD and NMR spectra
analysis and were found to form parallel GQ structures. Moreover, it has been previously
shown that RNA GQ structures are more stable compared to their DNA counterparts due
to the presence of the 2’hydroxyl group in the ribose sugar.
Following CD and NMR spectra studies, our collaborators at the Indian Institute
of Technology, Indore, India evaluated whether these GQ structures would interact with
the known GQ-binding ligands. GQ-binding ligands such as Braco-19, TMPyP4, etc.
have been widely studied to measure the stability of the GQ structures and are presently
being explored as an antiviral strategy (Ruggiero and Richter, 2018). The ligands bear
certain characteristics like basic aromatic rings, electron-deficient cationic core, and
positively charged side chains, which facilitate the efficient interaction of these ligands
with the GQ secondary structures (Vy Thi Le et al., 2012). The mode of interaction of
these ligands may be through end-stacking, groove binding, or interaction with the
backbone or loop sequences. The molecules fit themselves within these GQ structures
and bind through various non-covalent bonds thus stabilizing the structure. Further
biophysical studies including the fluorescence titration assay, ITC, and thermal
denaturation assays carried out by our collaborators conclusively demonstrated that
Braco-19 and TMPyP4 bind selectively and preferentially to the GQ-forming sequences
in comparison to the non-GQ linear RNA sequences. These studies unequivocally

137

demonstrated the existence and formation of GQ structures in the genome of ZIKV.
We reasoned that the binding of the Braco-19 or TMPyP4 could potentially
impact the function(s) of the viral RNA containing the GQ structures. The in vitro studies
that I conducted in cells infected with ZIKV and treated with Braco-19 or TMPyP4
suggested that both of these compounds inhibit the activities of the RNA template. Viral
protein synthesis was substantially reduced in a dose-dependent manner as evidenced by
the reduced levels of the E protein in the cells compared to control cells. Additionally, it
is possible that binding of these compounds to the GQ structures inhibited the movement
of the viral RNA polymerase, resulting in overall reduction of viral RNA copy numbers
as we have observed in our experiments. Although our studies revealed the existence of
multiple functional GQ structures in the viral genome, it would be interesting to examine
whether a particular GQ structure functions more prominently than the other structures.
Examination of E protein in ZIKV-infected cells treated with TMPyP4 revealed
slower migrating forms of the protein (Fig. 6A-B). The molecular basis for the reduced
mobility of E compared to that in TMPyP4-untreated cells is not clear at this time.
However, it is known that TMPyP4 becomes metabolized in cells through oxidation by
hemeoxygenase enzymes (HO-1 and HO-2) to produce 4-formyl-1-methylpyridinium
(4F-MP) and 4-carboxyl-1-methylpyridinium (4C-MP). Since these metabolites can bind
to certain cellular proteins such as acetylcholinesterase (Fujiwara et al., 2015), it is
possible that 4F-MP and/or 4C-MP bind specifically to the viral E protein in a time- and
concentration-dependent manner to reduce its mobility. Although our results are
consistent with such an interpretation, further research is needed to determine the
molecular basis of the observed mobility shift in the E protein.
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Taken together, our studies provide the first evidence that highly conserved GQ
structures present in ZIKV genome and the ligands that bind and stabilize these GQ
structures can potently inhibit ZIKV growth, genome replication, and viral protein
expression in cultured cells. However, the two ligands evaluated here are the most
common GQ-specific ligands used regularly to characterize these secondary structures
and are not highly specific to the particular ZIKV GQs. Moreover, the toxicity and
bioavailability of these ligands pose a hindrance for their potential use as antiviral drugs.
Although the results of my studies presented here stands as a proof of concept for using
GQ-binding ligands as anti-ZIKV drugs, development of sequence-specific ligands needs
further research. Moreover, the availability of ligands that can potentially target ZIKV
GQ sequences and that have the ability to distinguish them from the host GQs can
address the problem of off-target effects of the ligands. Thus, our results open the
possibility for understanding the role of GQ structures in ZIKV life cycle and
pathogenesis, as well as for use of these structures as targets for development of
innovative and efficacious antiviral strategies.
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CHAPTER VI: SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS

6.1. Summary
In 2015, ZIKV, a mosquito-borne flavivirus, re-emerged in Brazil and rapidly
spread in the Americas. In addition to causing previously known mild self-limiting
symptoms of flavivirus infections such as fever, headache, joint pain and rash, the
outbreak was implicated in the development of severe neurological and developmental
deficits in infants and demyelination and development of GBS in adults. Eventually,
global travel led to spread of the virus to other parts of the world and increasing reports
of such serious clinical manifestations of ZIKV infections were documented from many
countries. Owing to such serious pathological consequences, the World Health
Organization (WHO), declared the outbreak a global public health emergency in 2016.
While multiple antiviral drugs and vaccine candidates are being developed for use against
ZIKV infections, none have been approved for clinical use yet. The objectives of my
research described in this thesis were to develop and characterize vaccines and antiviral
therapeutics to mitigate ZIKV infections.
We used a nanoparticle-based vaccine platform, which utilizes ferritin, a
ubiquitous, self-assembling and naturally occurring protein that forms a nanoparticle to
display an organized array of an antigen on the surface of the nanoparticle. Such an
approach presents multiple copies of the antigen to BCRs leading to a stronger interaction
resulting in enhanced immune response in comparison to conventional strategies where
the soluble antigen interacts with BCRs with low affinity. In my studies, we
demonstrated formation of stable nanoparticles displaying the DIII domain of ZIKV E
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protein. Such nanoparticles induced much higher levels of neutralizing antibody response
and protected animals from lethal ZIKV challenge as compared to DIII alone as antigen.
These results provide a proof-of-principle for the approach to develop an efficacious
vaccine against ZIKV.
Additionally, we characterized an anti-ZIKV drug candidate, TPB that has shown
promising results in my studies. TPB was identified from a library of 100,000 compounds
that bound to the viral RdRp domain. TPB was shown to significantly reduce viral
replication in vitro and its administration significantly reduced viremia in infected mice.
With the IC50, and CC50 in the submicromolar and micromolar range, respectively and a
high selective index of over 200, TPB is a strong candidate for its development as an
antiviral drug against ZIKV infections.
The observation that ZIKV RNA genome may form non-canonical secondary
structures, called G-quadruplexes, prompted me to explore the possibility of re-purposing
anti-cancer drugs, BRACO-19 and TMPyP4, as anti-ZIKV agents. BRACO-19 and
TMPyP4 are small molecule G-quadruplex binding ligands that stabilize the Gquadruplex structures, and this leads to inhibition of cellular processes such transcription,
translation, and genome replication, etc. We found that exposure of ZIKV-infected cells
to either BRACO-19 or TMPyP4 led to a dose-dependent inhibition of ZIKV replication
in cells. Although, concerns about the bioavailability and toxicity of both compounds
exist at this time, further research on developing G-quadruplex binding ligands as
antiviral agents is needed.
Taken together, my dissertation focused on developing therapeutics (vaccines and
antivirals) to combat ZIKV infections. Fig. 6.1 summarizes the three objectives of my
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Fig. 6.1. Objectives and summary of results of the studies presented in my
dissertation.
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dissertation research identifying the viral replication steps for therapeutic intervention
and the results of the studies to achieve these objectives.

6.2. Conclusions
The following conclusions are drawn from the studies reported in this thesis.
1.

A ferritin-based nanoparticle carrying the DIII of ZIKV (zDIII-F) is stable and
induces high levels of neutralizing antibody response in vaccinated mice.

2.

Vaccination with zDIII-F protects mice from challenge with lethal dose of ZIKV.

3.

Passive transfer of antibodies from zDIII-F-vaccinated mice into naïve animals
confers protection against ZIKV challenge.

4.

ZIKV RdRp structure-based in silico screening led to identification of a small
molecule, TPB that potently inhibits the virus replication in cells in culture.

5.

TPB inhibits viremia in mice infected with ZIKV. TPB should be further
investigated for its potential as an antiviral against ZIKV/flavivirus infections.

6.

Targeting G-quadruplex structures present in the genome of ZIKV by ligands that
bind and stabilize these secondary structures results in inhibition of ZIKV
replication in vitro.

7.

G-quadruplex binding ligands should be explored further as potential anti-ZIKV
therapeutics.

6.3. Future Directions
6.3.1. Characterization of the dynamics of germinal center (GC) development
induced by zDIII-F vaccination
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In preliminary studies, we observed higher levels of lymph node germinal center
development in zDIII-F nanoparticle vaccinated mice by immunohistological staining in
comparison to mice vaccinated with DIII. GC development indicates generation of high
affinity antibody-secreting plasma cells and memory B cells that contribute to humoral
immunity (Laidlaw and Cyster, 2021). Therefore, it would be interesting to characterize
the development of GC with time after vaccination and assess the appearance of specific
B and T cells in response to zDIII-F. Using fluorescently tagged zDIII-F, we intend to
track the dynamics zDIII-F specific GC-associated B cell and T follicular helper cell
populations in secondary lymphoid tissues by cell imaging as well as by flow cytometry.
Transcriptomics and proteomics analysis of B and T cells isolated from GCs may identify
critical cellular factors that regulate enhanced GC development in the presence of zDIII-F
vaccine compared to DIII vaccine. This may provide an understanding of the possible
mechanism(s) of the development of a robust humoral immunity in response to zDIII-F
vaccination.

6.3.2. Investigation of other naturally occurring proteins as nanoparticle-based
vaccine delivery platforms.
While ferritin nanoparticle is composed of 24 subunits, other proteins such as
lumazine synthase, obtained from Aquifex aeolicus, can form nanoparticles that are
composed of 60 subunits (Ra et al., 2014). This property of lumazine synthase
nanoparticles can be exploited to display even higher number of antigenic epitopes on its
surface. Therefore, the strategy described in the construction of the ferritin-based
nanoparticle vaccine could be used for the development of a lumazine synthase
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nanoparticle-based ZIKV vaccine. Such a strategy may lead to higher number of BCRs
interacting with the epitopes exposed on the surface of the lumazine synthase
nanoparticle thereby leading to stronger immune response. The expectation is that the
efficacy of such a vaccine candidate will be significantly higher.

6.3.3. Development of a ferritin nano-particle based peptide vaccine using
immunoinformatics.
With the use of immunoinformatics, a developing field in vaccine research (Oli et
al., 2020), a small protein carrying multiple B and T cell immunodominant epitopes in
tandem found in the ZIKV proteins could be synthesized as a vaccine candidate. Several
such epitopes have been reported in ZIKV E and NS1 proteins (Prasasty et al., 2019).
Ferritin nanoparticles can be engineered to display an array of multiple copies of such
epitopes on the surface that can result in a better and more efficient B- and T- cell
responses thereby leading to a more efficacious nanoparticle-based vaccine.

6.3.4. Development of TPB as an anti-flaviviral drug
The structure of ZIKV RdRp was modelled based on the structure of DENV3
RdRp and it was found that TPB effectively inhibited ZIKV replication by allosteric
inhibition (Fig. 4.6A). Furthermore, the protein sequence of JEV, another flavivirus, is
known to be homologous to the protein sequence of ZIKV and DENV RdRp (Pattnaik et
al., 2018). Therefore, the possibility exists that TPB may also inhibit DENV and JEV
replication. Studies directed at examining the effect of TPB on DENV/JEV replication
may reveal if TPB could be developed as an anti-DENV and/or anti-JEV drug.
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6.3.5. Enhancement of the bio-availability of TPB.
Pharmacokinetics studies of TPB in mice revealed that it is cleared from
circulation with a short half-life and only ~100 ng/ml is detected after 10-12 hours.
Although this level of TPB was shown to inhibit ZIKV viremia in mice, increasing the
bioavailability of TPB may enhance its protective efficacy. It is known that physical
modifications such as nanomilling (Li et al., 2016b), micronisation (Chaumeil, 1998) or
the development of a TPB NanoSol (Lai et al., 2015) or chemical modifications such as
conjugation with cell penetrating peptides (Foged and Nielsen, 2008) can result in
significant increase in bioavailability of compounds. Therefore, studies to explore these
possibilities may result in enhanced bioavailability of TPB.

6.3.6. Studying the effect of other lead compound(s) identified from our screen on
ZIKV replication.
This dissertation focused on one compound (c1; TPB) from a list of ten lead
compounds that had high docking scores in in silico screening. Out of the ten compounds
that I examined initially, apart from TPB, c10 was also found to inhibit ZIKV replication
by ~80% at 1 M (Fig. 4.4). Further characterization of this compound may reveal
whether it can function as an anti-ZIKV/flavivirus.

6.3.7. Validation and targeted inhibition of specific G-quadruplex forming motifs.
Although many G-quadruplex structures were predicted to exist in ZIKV genome
and specific ligands that bind to these structures were shown to inhibit the virus
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replication, it is unknown which G-quadruplex structures play significant role in the
process. It has been reported that the formation of stable G-quadruplex structures leads to
suppression of transcription and translation of protein coding sequences that are
downstream of such motifs (Hershman et al., 2008; Verma et al., 2008). Therefore,
insertion of a particular G-quadruplex forming sequence upstream of the coding sequence
of a reporter protein, for instance, a fluorescent protein like GFP or RFP, and examining
its expression in the absence or presence of G-quadruplex binding ligands may suggest if
that particular structure contributes to the observed ligand-mediated inhibition of ZIKV
replication. Subsequently, conjugation of complementary DNA sequences upstream or
downstream of that particular G-quadruplex structure with a specific ligand may direct
the ligand to bind specifically to that particular G-quadruplex structure to inhibit virus
replication. Such an approach can be extended to other G-quadruplex structures and
binding ligands which can also be explored for their antiviral activities.

6.3.8. Exploration the molecular basis of the mobility shift in the viral E protein
with TmPyP4 treatment.
It was interesting to find that upon TMPyP4 exposure, there was a significant
concentration-and time-dependent mobility shift in the migration pattern of ZIKV E
protein as observed by Western blot analysis. TMPyP4 is known to be oxidized by
cellular heme-oxygenase enzymes (HO-1 and HO-2), to form 4-formyl-1methylpyridinium (4F-MP) and 4-carboxyl-1-methylpyridinium (4C-MP). Both 4F-MP
and 4C-MP are known to bind to certain intracellular proteins (Fujiwara et al., 2015). It is
possible that these metabolites also bind specifically to E protein of ZIKV and alter its
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mobility. While this may explain the shift in the observed migration pattern of ZIKV E
protein, experimental evidence is still lacking. Other yet unknown modifications induced
by the presence of TMTyP4 may also account the mobility shift. Experiments using mass
spectrometric analysis of isolated E proteins may suggest the type of modification(s)
occurring in E protein. Further, proteolytic digestion and mass spec studies may reveal
the site of modification in the protein.
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